Knight ADRC Resource Requests

Our Center has supported many investigators at Washington University and at other institutions over the years.  We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict.  To determine if your topic has already been studied with our resources, please search our database.  If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed.  You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID#, then it represents a research idea by an investigator but not fully submitted to the Knight ADRC. If the ID column contains Declared, a submission was made to the Declare Research Intent page and is not a formal request for resources.

 

 

Investigator Project Title Requested ID Aim 1 Aim 2 Aim 3 Aim 4
Alison Goate, D.Phil Genome-wide association study for late onset AD 4/16/2008 D0817
Chengjie Xiong The earliest antecedent markers of Alzheimer's disease 8/22/2008 D0818
Beau Ances Amyloid Imaging of HIV-Associated Neurocognitive Disorders (HAND) 9/4/2008 D0819
odity mukherjee Molecular genetics study of Alzheimer's disease in southern India 9/19/2008 D0820
Jim Galvin and Steve Duntley Sleep disturbance in AD and DLB 10/20/2008 D0823
jim galvin Biomarkers, Inflammation and Metabolic factors 10/20/2008 D0822
Jim Galvin AD8 analyses 10/20/2008 D0821
Milap Nowrangi, MD Correlation of Hippocampus Morphology in Alzheimerís Disease Patients with Performance on an Instrum 1/9/2009 D0902
Dorothy Edwards Barriers to Recruitment of African Americans for AD Studies 5/3/2009 D0903
Anders Dale Genetics of structural brain imaging phenotypes 5/8/2009 D0904
B. Joy Snider Diagnostic Accuracy of a Single Assessment in Alzheimer's Disease 6/5/2009 D0905
Dr Jin Moo Lee The neuronal injury biomarker VLP-1 correlates with dementia severity and brain atrophy in DAT 8/6/2009 D0906
paul nelson testing for a difference among three or more distributions 8/11/2009 D0907
Susan Stark The relationship between PIB status and physical performance 8/21/2009 D0908
Catherine Roe CSF accuracy 9/30/2009 D0909
manasi patil Artificial Intelligence 10/9/2009 D0910
manasi patil Artificial Neural Network based Diagnosis of Neuodegenerative Diseases 11/5/2009 D0911
Joel S. Perlmutter, MD Development & Validation of PCA-Based Analysis of PIB PET Data 1/14/2010 D1001
Holly Soares CAMD Biomarker Qualification 3/6/2010 D1002
Ashima Agarwal MD Alpha-synuclein pathology in Alzheimers Dementia with Lewy bodies, Lewy body dementia, and PD 3/23/2010 D1003
David Holztman/Alison Goate Identification of genetic factors associated with rate of progression 4/22/2010 D1004
John Morris Cognitive reserve, CSF, and cognitive decline 5/19/2010 D1005
Beau Ances The Relationship Amongst CDR Status, CSF Biomarkers, and Brain Functional Connectivity Networks 7/19/2010 D1006
Denise Head CSF Biomarkers and Cortical Thickness 7/22/2010 D1007
Denise Head Exercise, APOE and amyloid deposition 7/25/2010 D1008
John Morris Imaging of Cerebral Amyloid Burden in Acute Ischemic Stroke 8/2/2010 D1009
Tamara Hershey Case Study of Hypoglycemia vs. Controls 8/17/2010 D1010
John C. Morris Alzheimer mimics 8/26/2010 D1011 To increase the accuracy of diagnosis in neuropsychological and neuroimaging researches of AD
Tian Inference on diagnostic accuracy measures for diasease with three oridinal categories 9/7/2010 D1012 Inference about diagniostic measure with missing data Infrence about the prob. of correctly idetifying the intermidiate stage given sen. and spe.
Denise Head Exercise, Aging, and Functional Connectivity 9/8/2010 D1013
Eberlein, Timothy A R pacakge for diagnostic test for three ordinal groups 9/9/2010 D1014 A paper introduces a R package for volumne under ROC surface and Youden index calculation&inference The volumne ROC is built upon the paper by Chengjie Xiong 2006 Statististics in Medicine paper The Alzheimer marker dataset used in Xiong's paper is included in the R package as illustration The dataset is an existing dataset already used in Xiong's paper and the R package is public
Denise Head Obesity as a Moderator of Exercise Effects 9/10/2010 D1015 examine whether obesity moderates the effects of exercise on regional brain volumes and amyloid depo
Catherine Roe Predicting Post-stroke Dementia: Brain Reserve, Cognitive Reserve, and Amyloid 9/13/2010 D1016 To obtain preliminary data for grant proposal
Denise Head Multiple Factors Influencing Brain Networks 9/15/2010 D1017 Examine age effects on brain networks across the lifespan examine the influences of exercise, personality, amyloid and APOE genotype on brain networks
John Morris Cognitive reserve, brain reserve, and immediate stroke outcomes 10/7/2010 D1018 To determine whether cognitive and brain reserve factors influence immediate reaction to stroke.
Brian Gordon The Influence of Brain Structure on Prospective Memory 10/19/2010 D1019 Explore the relationship of medial temporal lobe volume and focal prospective memory Explore the relationship of prefrontal structures and non-focal prospective memory Investigate the influence of disease and genetic status on the link between behavior and anatomy
Dr. James Brewer Imaging studies of brain structure and function in aging and dementia 10/29/2010 D1020 Examine the relationship between brain atrophy and functional decline in aging and dementia Examine the relationship between brain atrophy and cellular biomarkers in aging and dementia Examine the relationship between brain atrophy and genetic markers in aging and dementia Examine the relationship between brain atrophy and intracranial amyloid load in aging and dementia
Halley Hindman Physical Activity, Cognition, and Regional Brain Volumes 11/9/2010 D1021 see Study Rationale
Mingan Yang, Chengjie Xiong Biostat modelling for Alzheimer's disease 11/15/2010 D1022 Develop flexible statistical methodology to study issues of Alzeheimer disease To improve the current methods, to address some issues the medical researchers are interested in
Jingqin Luo, Chengjie Xiong, Ming an Yang Random change point modele for longitudinal cognitive dementia 11/16/2010 D1023 It is hypothesized that a change point exists Alzheimer's disease patients will experience accerlerated dementa after the change point We will identify the change point in visuospatial score and logical memory jointly The relationship between the two change points helps clinical utilization of the two change points
Timothy M. Miller Understanding elevated SOD1 in CSF from AD patients 11/16/2010 D1024 Correlate SOD1 levels in CSF with other ADRC measurements on same patients
Csernansky, John G. Comparison of automatic analysis of hippocampal structure methods 2/27/2001 D0101
Cacchione, Pamela Z. The Accuracy of Collateral Source Reports in Assessing Individuals for Dementia 2/21/2001 D0105
Storandt, Martha The Effects of Age and Dementia on the Boston Naming Test (BNT) 4/23/2001 D0106
Powers, William CCCVD Sharing of Sequential Scans 6/26/2001 D0115
O'Brien, Richard Alternatives to MMSE for Screening 5/31/2002 D0208
Buckner, Randy L. Hypertension & structural/functional brain changes in healthy aging & early-stage DAT 6/24/2002 D0214
Bakal, Donald Algorithm for the Palm Pilot to derive CDRs in clinical practice 5/23/2003 D0312
Behrens, Maria Cancer in the elderly with and without Alzheimer's Disease. 10/30/2003 D0333
Behrens, Maria Follow-up of MAP patients with and without anticholinesterase inhibitors. 11/4/2003 D0334
Jacques, Genevieve Image Processing Project 11/7/2003 D0335
Xiong, Chengjie Education and the Course of Alzheimer's Disease 12/17/2003 D0401
Mintun, Mark A Pilot Study of C-11 PIB Brain Uptake and Binding 2/24/2004 D0406
Meuser, Thomas M. Dementia: An Atlas of Investigation and Diagnosis 2/25/2004 D0407
Verhoeff, Nicolaas, MD, PhD, FRCPC, DABPN 1/29/2004 D0408
Hagen,Jody Severity & Progression of Alzheimer's in African Americans & Caucasians 4/20/2004 D0416
Wells, William Statistical Atlas of Cortex and White Matter Anatomy 5/14/2004 D0420
Avidan, Michael Cognitive Dysfunction Following Surgery and Major Illness 8/10/2004 D0426
Meuser, Thomas M. Dementia Atlas Book Project 8/31/2004 D0429
Burns, Jeffrey Biomarkers in AD 9/10/2004 D0432
Lim, Wee-Shiong Effect of cerebrovascular lesions on AD 11/12/2004 D0435
Williams, Julie Identifying Genes forLate-Onset Alzheimer's Disease 9/12/2004 D0436
Johnson, David K. Weight loss in dementia 2/22/2005 D0511
Wilkins, Consuelo Obesity and Physical Performance in Older Adults 3/11/2005 D0514
Buckner, Randy L. Volume Decline Associated with Socioeconomic Privilege: Structural Neuroimaging in Older Adults 6/8/2005 D0515
Volandes, Angelo Eliciting Patient Preferences with Video 7/22/2005 D0521
Karakoc, Ebru Clinical, Neuropsychological and Imaging Correlates of MCI Subtypes 10/13/2005 D0526
Kauwe, John Evaluating SNPs that are associated with Late-onset Alzheimer's disease 1/18/2006 D0602
Bryan J. Traynor Genetic and pathological analysis of a ALS-FTD kindred 1/24/2006 D0603
Chiu, Grace Bent-Cable Regression for Longitudinal Data 3/1/2006 D0608
Galvin, James E. Relationship of Frailty to Longitudinal Cognitive Performance 3/3/2006 D0610
Karnik, Meghana Genetic Effects on Hippocampal Structure and Function 5/10/2006 D0612
Yushkevich, Paul Analysis of Hippocampal Thickness in AD 7/7/2006 D0617
Beg, Mirza Faisal early detection of AD via analysis of longitudinal MR scans 8/11/2006 D0619
Wang, Lei Structural Imaging to Improve the Early Detection of AD 10/23/2006 D0623
Karam, George Effect of grief on dementia 12/4/2006 D0628
Head, Denise Diabetes and Cognitive Decline in Nondemented Older Adults 12/12/2006 D0703
Head, Denise Aging and Physical Activity 12/15/2006 D0704
Buckner, Randy L. Exploring network disruption in aging independent of AD 1/24/2007 D0708
Goate, Alison PIB retention as an endophenotype for AD 2/21/2007 D0710
Dickerson, Brad Genetic influences on cortical thickness: AD vs Age 4/3/2006 D0713
Wilkins, Consuelo Vitamin D in Older Adults: Cognition, Mood, and Hippocampal Volume 1/20/2007 D0715
Shannon, Benjamin Brain Function, Structure, and Clinical Outcomes in Aging and Alzheimer's Disease 7/31/2007 D0721
Carr, David Fitness to Driver in Neurologically Impaired Older Adults 8/8/2007 D0722
Roe, Catherine CDR Drift 8/1/2007 D0723
Wilkins, Consuelo Physical Performance and Risk of Dementia 10/8/2007 D0729
Roe, Catherine Education, Cognitive Reserve, and PIB 10/26/2007 D0730
Roe, Catherine Education, Cognitive Reserve, and Prediction of Dementia using Amyloid Imaging 11/16/2007 D0802
Maue Dreyfus, Denise Autobiographical recall of recent events 12/3/2007 D0804
Dickerson, Brad Influence of brain amyloid on regional cortical thickness and psychometrics 1/22/2008 D0808
Roe, Catherine Memory Complaints in Individuals without Cognitive Impairment 2/18/2008 D0812
Williams, Monique Vascular Risk Factors in Alzheimer Disease 2/27/2008 D0816
Gina D'Angelo Missing data approaches for partial correlations of regional volumetric data 11/29/2010 D1025 Extend the partial correlation coefficient in the presence of missing data using the EM algorithm Use (1) to study relationships among regional brain measures while adjusting for other variables
B. Joy Snider Genotype-Phenotype Correlations in Dominantly Inherited Dementing Disorders 12/1/2010 D1026 Look for correlations between clinical phenotype with mutation in those with known mutation look for correlation between rate of progression and mutation preliminary analysis of biomarkers in known mutations preliminary analysis of PET_PIB in known mutations
David B. Carr, MD Functional Impairment in PIB+ Healthy Older Adults 1/11/2011 D1101 Is there a lower prevalence of active drivers in PIB+ CDR=0 participants? Of the active driver pool, are PIB+ CDR=0 drivers believed to be at more risk than PIB-? Is functional impairment (FAQ) more prevalent in PIB+ CDR=0 participants? Do PIB+ CDR=0 participants have a higher rate of functional decline over time?
Carolyn Baum Contribution to a Metaanalysis on Apraxia 6/10/2011 D1116 To respond to a request from Francois Osiurak, PhD, for data that was already published
Dr. Denise Head Effects of the BDNF polymorphism and exercise on brain structure, AD biomarkers and cognition. 1/22/2011 D1102 examine the effects of the BDNF polymorphism on brain, cognition, and AD biomarkers examine interactions between the BDNF polymorphism and exercise examine interactions between the BDNF polymorphism and age examine interactions between the APOE and BDNF polymorphisms
Luigi Maccotta Functional Connectivity in Epilepsy 2/16/2011 D1103 To characterize changes in local and long-range functional connections in temporal lobe epilepsy To characterize connectivity changes in TLE patients with grossly normal brain anatomy
Dr. John Morris Age of Onset Disparities among first degree relatives 2/17/2011 D1104 To determine the causes for AOO disparities among first degree relatives
Catherine M. Roe IMPROVING PRESYMPTOMATIC DETECTION OF IMPENDING ALZHEIMERíS DISEASE 2/28/2011 D1105 To examine how cognitive and brain reserve factors combine with AD biomarkers To build biomarker models that yield individual risk profiles predicting the time of AD onset.
B. Joy Snider, Anne Fagan CSF biomarkers and rate of cognitive decline in very mild DAT 6/13/2011 D1117 Look for correlation between CSF biomarkers and rate of decline in very mild DAT look for correlation between ApoE genotype and rate of decline in very mild DAT
Andrei Vlassenko Regional beta-amyloid deposition in cognitively normal older adults 1/21/2012 D1201 Examine regional differences in PIB BP in PIB-negative older compared to younger adults
Allitia DiBernardo ADRC data modeling to support DIAN trial planning 2/5/2012 D1202 Establish longitudinal biomarker profiles in amyloid+ cogntively normal subjects Establish longitudinal cognitive profiles in amyloid+ cognitively normal subjects Establish longitudinal biomarker profles in amyloid+ MCI subjects Evaluate cognitive composites for CN and MCI amyloid+ subjects
Dave Balota The Effects of Alzheimer’s Disease and Aging on Cortical Myelination 2/20/2012 D1203 Estimate changes in cortical myelination in healthy aging Estimate changes in cortical myelination in Alheimer's disease Examine the robustness of this technique in two independent samples of healthy older adults
Xiong ROLE OF IMPAIRED COGNITIVE STATES & RISK FACTORS IN CONVERSION TO MIXED DEMENTIAS 2/21/2012 D1204 To merge databases from 6 large projects to rigorously analyse longitudinal data to identify intervening states between normal cognition and dementia to study transitions and associated risk factors to standardize neuropathological across databaese to allow analysis of novel pathogenic determinantc
Joshua Shimony Resting State Networks (RSN) in Cerebrovascular Disease 3/1/2012 D1205 Compare RSN in patients with cerebrovascular to age matched normal controls.
Chengjie Xiong Two Preclinical Latent Scores to Predict Occurrence of DAT 3/22/2012 D1206 Assess the antecedent longitudinal changes and their predictive power of DAT for individual items of Aim 2. Evaluate the use of IRT Develop clinically meaningful score reports
Jonathan Day Assessment of Current Alzheimer's Disease Therapies Using Neuroimaging and CSF Biomarkers: A Pilot S 3/1/2011 D1106 Assess the effectiveness of AD therapies from a neuroimaging and biomarker standpoints
Jason Hassenstab Obesity, Insulin Sensitivity, and Functional Connectivity in Normal Aging 3/1/2011 D1107 Do CDR 0's with obesity and insulin resistance perform poorly on memory and executive function? Do CDR 0's with obesity and insulin resistance have reduced functional connectivity? Do CDR 0's with obesity and insulin resistance have lower brain volumes/cortical thickness?
Mark McDaniel The Effects of Hypertension and Abnormal Blood Pressure on Prospective Memory 4/28/2011 D1108 Assess the effects of hypertension on focal versus nonfocal prospective memory (PM) performance Determine whether gray matter volume mediates the relationship between hypertension and PM Determine whether white matter integrity relates to focal PM, nonfocal PM, or hypertension
John C Morris Multimodal biomarker prediction 5/6/2011 D1109 Evaluate biomarker combinations that predict clinical outcomes in cognitively normal and DAT persons
Joel Perlmutter Effects of Parkinsonís Disease on BOLD Functional Connectivity 6/13/2011 D1118 Study effects of PD on BOLD FC in subcortical areas
Alison Goate Genetics of CSF endophenotypes for AD 5/6/2011 D1110 To identify genes that influence the CSF levels of AD biomarkers
Alison Goate TOMM40 and neuroimaging phenotypes 5/6/2011 D1111 Test hypothesis from Mark Sager regarding relationship between TOMM40 genotypes and neuroimaging phe
James Galvin Utility of the AD8 in Mild Cognitive Impairment 5/20/2011 D1112 Determine the psychometric properties of the AD8 to discriminate MCI from healthy controls
Siekyeong Kim Relationship of Cortical Thickness to Brain Morphology and Body Size 5/23/2011 D1113 What is the relationship between cortical thickness and head size? Are there differences in the above relationship by CDR status?
Bruno M. Jedynak Statistical Analysis of the Progression of AD 5/26/2011 D1114 Validate the findings from ADNI data using ADRC data
Dr. John C. Morris The rule of sleep, personality, and aging: How these interactions affect cognition 6/24/2011 D1119 When comparing CDR 0 to CDR 0.5, 0.5's would have higher levels of neuroticism & sleep difficulties Within CDR0, those with high neuroticism & sleep difficulties will have lower cognition performance Of those who progress to higher CDR, more of the high neuroticism and sleep problems group High neuroticism group show more awakening and activity on actigraphs
John C. Morris Correlation of AD biomarkers with CDR 0.5 diagnoses 5/26/2011 D1115 Correlate PIB retention with CDR 0.5 diagnoses Correlate CSF levels of Abeta and tau with CDR 0.5 diagnoses Correlate nWBV and hippocampal volume with CDR 0.5 diagnoses Correlate pyschometric performance with CDR 0.5 diagnoses
Jessica Nichols (student in Friedman Program) Effect of Type 2 Diabetes Mellitus on Resting State Functional Connectivity 7/6/2011 D1120 look at how T2DM affects resting state functional connectivity and if it is a risk factor for AD
Robyn A Honea The Role of Genetic Variation in Alzheimer's Disease Neurodegeneration 7/6/2011 D1121 Assess the relationship of selected candidate genes with MRI phenotypes and cognitive markers of AD
Joanne Conover Ventricular Expansion and Leakiness in Normal Aging 9/20/2011 D1122 Regional Trends in Expansion and Hyperintensities Using FLAIR-MRI
Denise Head The Relationship Between Stress and Biomarkers of Alzheimer's Diseases 9/29/2011 D1123 To determine the relationship between stress exposure and AD biomarkers To investigate whether stress exacerbates the effects of age on AD biomarkers To examine whether stress exacerbates the effects of APOE e4 and/or met-BDNF allele on AD biomarkers To examine the interaction effect between stress and exercise on AD biomarkers
David Holtzman/Alison Goate To identify genetic variation that influences VILIP1 levels in cerebrospinal fluid 10/18/2011 D1124 To identify polymorphisms that explain variability in CSF VILIP1 levels.
Carlos Cruchaga/Alison Goate To test whether the poly-T polymorphism (rs10524523) is associated with change in gray matter volume 10/18/2011 D1125 Try to replicate the Dr. Sager neuroimaging findings in a larger series
David Holtzman Clinicopathologic Characterization of Late-Onset Autosomal Dominant AD 10/24/2011 D1126 Identify clinical charactersitics of family LO6 who harbor PSEN1 A79V mutations Examine CSF and Imaging biomarkers in individuals from family LO6 Compare clinical and biomarker data between LO6 and early-onset kindreds with PSEN1 A79V mut
Brian Carpenter Ability of Collateral Informants to Describe Patient Functioning 10/26/2011 D1127 Determine the base rate of collaterals who are rated as having questionable or poor accuracy Determine the base rate of reasons for collateral inaccuracy
Danny JJ Wang Complexity and synchronicty of resting state fMRI time-series in Alzheimer's disease 11/2/2011 D1128 To quantify the complexity of resting fMRI using ApEn in AD, MCI and NC subjects To quantify the asynchrony of resting fMRI using C-ApEn and compare with cross-correlation
Melanie Bauer Relation between Working Memory, Long-Term Memory, and Fluid Intelligence 11/7/2011 D1129 Examine relationships between areas of cognition: working and long-term memory & fluid intelligence These relationships will be compared in healthy and cognitively impaired older adults. If possible, longitudinal changes in memory will be compared to changes in fluid intelligence
Sandra Chapman Early Markers of Language Dissolution in HDDD2 11/11/2011 D1130 Explore relationshp between language and clinical/genetic profiles of HDDD cohort Examine changes in discoures measures for individuals rested in follow-up Explore relationship between changes in disourse and performance on neuropsych
Yvette Sheline Hippocampal subfield segmentation comparison in LLD, AD and controls 11/22/2011 D1131 1) Compared with controls, patients with LLD will have smaller hippocampal subfield volumes in denta 2) LLD patients will have progression in CA2-3 volume loss related to interim perceived stress durin 3) Compared with controls, CDR = 0.5 participants will have significantly hippocampal volunes, parti 4) Across all groups DG volumes will correlate inversely with MCBP on PIB PET
Catherine M. Roe Alzheimer's disease biomarkers and cancer 4/6/2012 D1207 To examine whether Alzheimer's disease biomarkers are associated with cancer
Zheyu Wang Biomarker Evaluation in the Absence of a Gold Standard 5/17/2012 D1208 Methodology development on evaluating biomarkers in the absence of a gold standard
Phillip Hsu Risk factors associated with Headache due to Lumbar Puncture 6/30/2012 D1209 To identify risk factors that increase the likelihood of a post-Lumbar Puncture headache
Brooke Sadler The Evolutionary Role of Nicotinic Receptors in Memory and Cognitive Performance 7/6/2012 D1210 Examine association between genotypes in nicotinic receptors with phenotypes related to cognition Determine if these genotypes are at different frequencies among AD vs non AD participants Relate these frequency differences back to historical selective pressures on increased cognition
Charles DeCarli NACC MRI Genotype Association Studies 7/6/2012 D1211 Acquire MRI data related to TCV and Hippocampal estimates from NACC participating sites Match MRI data with ADGC acquired genotype data on NACC enrolled subjects Examine candidate gene associations from prior publications
Alison Goate/Oscar Harari Identification of genetic factors associated with rate of progression 7/24/2012 D1212 To replicate the association of rs1868402 with rate of progression To analyze whether other genetic factors associated with CSF ptau181 levels
Alison Goate Clinicopathological correlations of MAPT A152T mutation carriers 7/24/2012 D1213 Characterize clinical phenotype of MAPT A152T mutation carriers Characterize pathological phenotype of MAPT A152T mutation carriers Characterize molecular phenotype of MAPT A152T mutation carriers
Rachel Chasse Enhancing Normative Cognitive Data with Information from Biomarkers and Neuroimaging. 7/25/2012 D1214 Assemble a normative cognitive database informed by biomarker evidence of AD neuropathology. Determine if this 'super' normative database will improve early detection of cognitive decline.
Catherine M. Roe Use of Alzheimer's Disease Biomarkers to Predict Longevity and Disability 8/24/2012 D1215 To examine whether AD biomarker levels in cognitively normal persons predict longevity and disabilit
Napatkamon Ayutyanont Development of Composite Cognitive Endpoints for Presymptomatic AD Trials 8/27/2012 D1216 To refine composite endpoints previously developed to track cognitive changes leading to onset of AD To establish generalizability of the implicated composite endpoint in other longitudinal datasets To provide prelim. sample size estimates for proposed presymptomatic AD trials (API’s, ADCS’s, etc.)
Beau Ances MD, PhD The Effects of Autosomal Dominant and Sporadic Alzheimer Disease on Intra and Inter-Network Resting 9/24/2012 D1217 We will assess participants with (M+) and siblings without (M-) adAD mutations that are followed in We will compare these individuals to participants from multiple studies conducted at the Knight Alzh
Tae Sung Lim A corticobasal degeneration case mimicking Alzheimer's disease 10/2/2012 D1218 Determine the clinical characteristics of CBD case mimicking AD Clinicopathological correlation of CBD case mimicking AD
Robert Koeppe Standardizing Biomarker Reporting for Amyloid Plaque Estimation by PET 10/9/2012 D1220 To provide a standard method for quantifying scaling of amyloid burden with PET The quantification scale would be applicable to different radiotracers The quantification scale would be applicable to different analysis methods Methods for conversion of SUVr or DVR results into the standard scale will be developed
Gina D'ANgelo Groupwise approaches for functional connectivity 10/12/2012 D1219 develop population-level inter-regional approaches for resting-state fMRI develop population-level network approaches for resting-state fMRI
JC Morris Testing the hypothesized stages of pre-clinical AD 10/16/2012 D1221 Identify the NIA-AA stages of preclinical AD by CSF markers in cognitively normal individuals Investigate the predictive accuracy of these stages for cognitive and clinical decline
Chengjie Xiong Wavelet-based statistical analysis on brain functional connectivity 10/24/2012 D1222 Develop novel quantitative tools to comprehensively measure brain functional connectivity Develop novel stat. methods to identify impairments of brain func. connectivity in elderly individua
Daniel Marcus Development of a tool for quantitative analysis of MRI and PET in clinical dementia 11/6/2012 D1223 NA (this is not a research project)
Xiong Yunyun The association between PiB retention and cognitive decline 1/11/2013 D1301 a meta analysis investigating the prognostic value of baseline PiB status on the development of AD
Yuan-Han,Yang ACE gene in AD with hypertension among African American and Caucasian American 1/12/2013 D1302 Examine the association of ACE gene in LOAD with / without hypertension in CA and AA Examine the clinical course of LOAD in relation to their ACE indel polymorphism in CA and AA.
Beau Ances MD, PhD, MSc 1/22/2013 D1303 To explore novel complex measures using multi-scale entropy in rs-fcMRI data from an HASD cohort.
John C. Morris Investigating COMT and Intraindividual Variability 2/1/2013 D1304 Determine whether COMT is independently related to intraindividual variability in reaction time.
Cruchaga Carlos Identification of rare variants implicated on Alzheimer’s Disease 2/5/2013 D1305 To identify and better understand the neuropathological findings for the PSEN1, p.E318G carriers
Adam Ingber Reserve variables and the relationship between AD biomarkers and non-cognitive outcomes 2/6/2013 D1306 To examine how cognitive and brain reserve measures mediate associations between AD biomarkers and n
Swerdlow A predictive prognostic model for Alzheimer’s disease 2/18/2013 D1307 Evaluate the reproducibility of the Bayesian Belief Network (BBN) in autopsy-confirmed AD : Evaluate convergent validity of the BBN by comparing the model diagnoses to expert diagnoses Extend the neurocognitive-based BBN to include KADRC biomarker data
B. Joy Snider Role of Cerebrospinal fluid studies in Diagnosis and Treatment of Dementing Disorders at MDC 3/2/2013 D1308 Characterize patients selected for CSF analysis as part of dementia evaluation Determine if CSF results, specifically disease-related biomarkers, change diagnosis or treatment
Kathleen Vernon Lateralization of Atrophy and Behavioral Disturbance in AD 3/4/2013 D1309 Determine if lateralized brain atrophy in mild AD is related to types of behavioral disturbance.
Terrance Kummer Axon injury in intracerebral hemorrhage 3/4/2013 D1310 Determine the extent of local and global acute axonal injury after ICH using diffusion tensor imagin Examine the sub-acute evolution of local and global axonal injury following ICH Examine the chronic evolution of local and global axonal injury after ICH, and determine which is be Compare radiological biomarkers of axonal injury resulting from ICH with biochemical biomarkers obta
John c Morris Noncognitive markers of preclinical AD 3/14/2013 D1311 Correlate Hgb A1c, body mass index, and related markers (eg, body wieght) with biomarkers in preclin
JC Morris PIB negative but cognitively impaired 3/28/2013 D1312 Evaluate possible reasons for the discordance between clinical status and imaging biomarker status
Grant - John C. Morris, MD. This project - Jennifer Phillips Factors Influencing Assent for Brain Donation 5/16/2013 D1313 To examine data from the past ten years and determine the time that participants are most likely to
Yaakov Stern A new prediction algorithm for mortality and nursing home admission. 5/31/2013 D1314 To validate a prediction algorithm.
Anne Fagan and Maartje Kester APOE genotype and CSF biomarkers in predictive models for cognitive decline and Alzheimer’s disease 6/9/2013 D1315 to look at the effect of APOE genotype on the diagnostic and prognostic ability of CSF biomarkers.
Beau Ances Comparing Functional Connectivity and CSF in Autosomal Dominant and Late Onset AD 7/8/2013 D1316 Characterize relationship between CSF & functional connectivity in autosomal dominant AD (ADAD). Compare relationship between CSF and FC for ADAD and late onset AD (LOAD).
Pau Pastor Clinical and neuroimaging characterization of Alzheimer TREM2 p.R47H carriers 8/1/2013 D1317 To compare clinical featuresof Alzheimer TREM2 p.R47H carriers vs noncarriers and ctrl To compare neuroimaging features (MRI) by VBM of Alzheimer TREM2 p.R47H vs noncarriers and controls
Stephanie Vos Prevalence of amyloid pathology in healthy and cognitively impaired individuals 8/21/2013 D1318 To characterize amyloid prevalence according to baselin cognitive scores (CDR, MMSE, delayed recall) To characterize amyloid prevalence according to age, apoE genotype To characterize amyloid prevalence according to future cognitive scores (CDR, MMSE, delayed recall)
CAMD consortium CAMD request for biomarker data 9/12/2013 D1319 FDA biomarker qualification Alzheimer's disease progression modeling
Carlos Cruchaga Identification of genetic variants associated with AD progression rate 10/11/2013 D1320 Psychometric scores from the different test and contributed sites will be combined A GWAS will be running using several psychometric test as endophentypes
JC Morris Validation of the AD8 10/21/2013 D1321 Determine AD8 scores for all participants at baseline since Sept 2005 who later came to autopsy Correlate AD8 positive and AD8 negative individuals with neuropathological diagnoses Correlate AD8 scores with subjective memory complaints
John C Morris Crossed Alexia without Agraphia in Progressive Posterior Cortical Dysfunction caused by Alzheimer’s 11/4/2013 D1322 Report the first case of pathologically proven crossed alexia without agraphia in a posterior cortic
John C Morris Examine neuropathological correlates of subjective memory complaints 11/4/2013 D1323 . Describe the relationship between main neuropathological findings of Alzheimer‚Äôs disease (ő≤-amyloi Clarify the role of the accompanying neuropathological findings (white matter change, ischemia, infa Determine what neuropathological finding is the best candidates to explain SMC. Compare other clinical and biological variables (CDR-SB, ApoE,) between participants with or without
Catherine Roe Use of Alzheimer’s Disease Biomarkers to Predict UPDRS Symptoms 12/6/2013 D1324 To examine the extent to which AD biomarker levels in cognitively normal persons predict PD symptoms to examine the extent to which AD biomarkers predict rate of change of parkinsonian symptoms in individuals with AD at baseline.
Denise Head Cognitive profiles in the Adult Children Study 12/9/2013 D1325 Confirm the the latent factor structure of the psychometric battery for the Adult Children Study Test potential differences in factor structure based on family history of AD Test potential differences in factor structure based on APOE status Test potential differences in factor structure based on age
Ien Li Patch-Based Analysis of Anatomical Brain Asymmetry 1/3/2014 D1401 Compare structural hemispheric brain asymmetry patterns in diseased individuals versus healthy controls Assess cognitive measures with brain asymmetry from structural MRI scans
Jennifer Molano The Effect of Alzheimer‚Äôs Disease Biomarkers and Sleep on Cognitive Performance 1/24/2014 D1402 CSF levels of Aő≤42, tau, ptau181, tau/Aő≤42, and ptau181/Aő≤42 indicating AD pathology will be associated with worse psychometric performance on tests of memory and/or executive functioning among cognitively normal adults, both cross-sectionally and longitudinally. Sleep efficiency will be an effect modifier on psychometric scores, with worse sleep efficiency correlating with worse psychometric performance on tests of memory and/or executive functioning cross-sectionally and longitudinally, after accounting for any effect of CSF AD biomarkers. termine if
Tae Sung Lim Neuropathological features of slowly progressive dementia 2/20/2014 D1403 To compare the neuropathological features between DAT with and without progression in global CDR 0.5 and 1
Anish Mitra The Gene expression basis of amyloid distribution in Alzheimer's Disease 3/1/2014 D1404 Relate spatial patterns of gene expression to the spatial topography of amyloid distribution in the brain Investigate genes whose spatial expression profile matches amyloid and aerobic glycolysis in the brain
Stark, Susan L. Functional Loss as a Non-cognitive Marker of Preclinical AD 3/4/2014 D1405 Determine the prevalence of functional decline related to the systemic deficits of AD among older adults with preclinical AD (defined by AD biomarkers) Identify the relationship of functional decline to preclinical AD (defined by AD biomarkers)
John C. Morris Association of Lewy Body Pathology with UPDRS Motor Scores, Neuropsychiatric Symptoms, and Depression Scores among Persons with Neuropathological AD 3/5/2014 D1406 To examine the associations between Lewy Body pathology and motor, neuropsychiatric, and depression symptoms in participants with neuropathological AD
Carlos Cruchaga Identification of novel genes and variants associated with Alzheimer’s disease and other complex traits by using CSF and plasma analytes levels as quantitative traits 3/6/2014 D1407 To identify common genetic variants associated with CSF and plasma protein levels To identify low-frequency coding variants and genes associated with CSF plasma protein levels
jason Hassenstab Staging Preclinical AD With the Free and Cued Selective Reminding Test 3/6/2014 D1408 To operationalize the "subtle cognitive deficits" that define Stage 3 preclinical AD To determine if the FCSRT+IR is an optimal measure to predict progression to symptomatic AD
Sebastian Palmqvist, MD, PhD Comparison of large cohorts examining AD biomarkers 3/10/2014 D1409 Verify the number of patients that have undergone CSF, PET, MRI, and examine the follow-up time and inclusion/exclusion procedures Compare this to other large cohorts such as AiBL, ADNI, Descripa among others.
Denise Head Effects of the mineralocorticoid receptor polymorphisms and plasma cortisol on brain structure, cognition and personality 3/17/2014 D1410 To examine the effect of the two single nucleotide polymorphisms in the mineralocorticoid receptor on brain structure, cognition and neuroticism To examine whether the mineralocorticoid receptor genotypes interact with plasma cortisol
Catherine Roe Alzheimer‚Äôs Disease: AD Biomarkers and Lipids 3/25/2014 D1411 To examine the cross-sectional and longitudinal associations between lipids levels in the plasma and AD, dementia, and CSF AD biomarkers, including Aő≤42, tau, and ptau181.
Carlos Cruchaga To identify genetic variation that influences YKL40 levels in cerebrospinal fluid 6/19/2014 D1412 To identify genetic variation that influences YKL40 levels in cerebrospinal fluid
Jesse Mez A liability model to increase power in genome-wide association 7/1/2014 D1413 To carry out genome-wide association in ADGC African American AD cases and controls using residuals from a liability model that includes genetic and non-genetic risk factors as a quantitative phenotype To carry out genome-wide association in ADGC white AD cases and controls using residuals from a liability model that includes genetic and non-genetic risk factors as a quantitative phenotype
Dr. John Carl Morris an item-level analysis of frequently missed items on the Mini Mental Sate Exam in cognitively normal older adults 7/7/2014 D1414 Determine which items on MMSE are most frequently missed by CDR0 adults Determine if these items relate to demographic characteristics and family history Perform a survival analysis to determine if certain items are associated with future progression to AD
Steven G. Younkin Association of Sickle Cell Trait With Alzheimer's Disease 7/9/2014 D1415 Determine if sickle cell trait (SCT) is associated with Alzheimer's Disease Determine if there is a significant interaction between age and the association of SCT with LOAD
Dale Bredesen, M.D. ADAD-associated neuropathology from the NACC database 8/12/2014 D1416 Compare and contrast the prevalence of amyloid angiopathy in persons with ADAD relative to LOAD Compare and contrast the prevalence of lewy body pathology in persons with ADAD relative to LOAD
Linda Larson-Prior Cognitrive fluctuations in aging and dementia 8/27/2014 D1417 To determine the neural network changes that differentiate individuals with cognitive fluctuations from age-matched cognitively normal adults To determine whether neural network changes associated with cognitive fluctuations differ from changes in those with mild cognitive dysfunction in individuals matched by age and CDR rating
Linda Larson-Prior Geriatric Atlases for functional EEG and neurostimulation therapy of aging brains 9/3/2014 D1418 Determine whether patterns of atrophy based on CSF volume differ between adults with no amyloid burden vs a mixed population between the ages of 50-100 years Define and test a morphometric feature space that describes discrete age-group clusters that differ significantly in those features Create and test age-cluster head models for use in neurostimulation and electrical source imaging studies
Gregory Day Identifying clinical and paraclinical predictors of rate of progression in dementia (RaPID) 9/18/2014 D1419 1. To characterize clinical and paraclinical measures in participants with suspected and/or confirmed rapidly progressive dementia. 2. To identify clinical and paraclinical measures that predict final diagnoses in patients with rapidly progressive dementia. 3. To identify clinical and paraclinical measures associated with rapidly progressive, typically progressive and slowly progressive dementia. 4. To identify clinical and paraclinical measures that predict rate of progression in dementia.
Carlos Cruchaga Identification of genetic factors associated with rate of progression 9/24/2014 D1420 To analyze whether other genetic factors associated with CSF ptau181 levels also are associated with progression rate. We are currently performing a GWAS analysis using CSF ptau181 levels as phenotype and we want to test the top hit from this analysis for association with progression rate.
John Morris NIA-AA staging using multiple biomarkers 9/29/2014 D1421 To comparing NIA-AA staging criterion using both CSF and imaging biomarkers
Denise Head Inflammation as a mediator of age, personality and exercise associations with brain structure 10/8/2014 D1422 Examine whether inflammatory markers mediate the relationships of aging, personality traits and exercise with regional brain structure.
Perrin, Richard Novel Fluid Biomarkers Associated with PIB-PET Imaging 10/13/2014 D1423 Identify fluid biomarkers associated with PIB positivity among CDR0 participants Identify fluid biomarkers that predict conversion to PIB positivity among PIB negative CDR0 participants Identify fluid biomarkers that predict progression to CDR>0 among PIB positive CDR0 participants
John C Morris Accelerators and Protectors of Tranistioning to Symptomatic AD 10/26/2014 D1424 Examine Adult Choildren Study participants who have been rated CDR>0 Compare their clinical, cognitive, imaging, biofluid, and genetic features with ACS participants who remain CDR0
Carlos Cruchaga Identification of genetic variants associated with AD progression rate 10/29/2014 D1425 Identification of genetic variants associated with AD progression rate
Anne Fagan and David M. Holtzman Assessing Different Forms of Tau Protein in Cerebrospinal Fluid as an Alzheimer Biomarker 4/1/2008 T0818
Vincent Marchesi a blood test for Alzheimer's disease 4/14/2008 T0819
Nupur Ghoshal ApoE4 antibody titration 6/24/2008 T0820
David Brody Amyloid-beta oligomer quantitation 9/8/2010 T1017 To determine the concentration of amyloid-beta oligomers in extracts from human brain Assess oligomer concentrations in brains from demented and non-demented with equivalent plaques
Scott E. Counts, Ph.D. Proteomics of mild cognitive impairment in the elderly 3/17/2008 T0817
Stuart Pickering-Brown Genetic analysis of FTLD-U 6/24/2008 T0821
Rawan Tarawneh Ab40ox and a-synuclein as potenential CSF biomarkers for the diagnosis of Dementia with Lewy Bodies: 6/26/2008 T0822
Randall Bateman CSF Tau IP-MS 7/8/2008 T0823
Dr. Sara Mole Molecular genetics and biology of the neuronal ceroid lipofuscinoses 7/18/2008 T0824
William Klunk PIB binding in post mortem human brain tissue 9/8/2008 T0825
Ryan C. Bailey Development of a Scalable, Pre-clinical Alzheimerís Diagnostic Panel Based upon Silicon Photonics 10/22/2010 T1018 Validation of an emerging technology for pre-clinical AD diagnostics via multiplexed CSF proteomics
Z. K. Wszolek Discovering the genetic cause of hereditary diffuse leukoencephalopathy with axonal spheroids 10/29/2008 T0826
Sidney Strickland Association between fibrin(ogen) and Abeta in Alzheimer's disease 11/18/2008 T0827
David Holtzman Neurohistochemical Investigation of Potential Novel Biomarkers of AD 12/14/2008 T0828
Moskowitz, David W. Leukocyte genomic DNA from healthy nonagenarians and centenarians 4/24/2000 T0001
Han, Xianlin Sulfatide Deficiencies in Cellular Membranes of Gray Matter 10/30/2000 T0002
Galvin, James E. Role of Interstitial Neurons in Neurodegenerative Dementias 8/8/2000 T0003
Prof. Dr. Christian Haass / Dr. Sven Lammich Regulation of the a-secretase ADAM10 12/23/2008 T0829
Mark A. Lovell Validation of a Novel CSF ELISA for Diagnosis of AD 2/6/2009 T0901
Michael Harrington Amino Acid Metabolome biomarkers in Alzheimer's disease 2/12/2009 T0902
David M. Holtzman Neuroinflammatory Biomarkers for Alzheimer's Disease 2/24/2009 T0903
Dr David Holtzman The utility of the novel marker Visinin-like protein (VILIP-1) in the diagnosis and prognosis of DAT 11/2/2009 T0920
Timothy Miller Examining SOD1 Protein in CSF 11/20/2009 T0921
Gregory J Zipfel Cerebral Amyloid Angiopathy, Vascular Dysfunction & Ischemic Brain Injury 12/7/2009 T0922
Heinecke, Jay Elevated Myeloperoxidase Levels in Hippocampuses of Patients with Alzheimer's Disease 4/24/2000 T0006
Wabl, Matthias Alzheimer's Disease and Parkinson's Diseases Caused by Mutations in Critical Genes? 4/24/2000 T0007
Conrad, Craig The Use of Biomarkers to Evaluate the Progression AD 6/26/2000 T0009
Bob Baloh Mechanisms of neurodegeneration from mutations in TDP-43 3/2/2009 T0904
David Holtzman, Alison Goate SNPs in catalytic and regulatory subunits of calcineurin are associated with CSF tau protein levels, 3/2/2009 T0905
Alison Goate Study of genetic variants associated with granulin plasma levels 3/2/2009 T0906
Zhukareva, Victoria Taupathies: Genotype and Phenotype 10/12/2000 T0010
Wu, Jane The Role of Alternative Splicing in Neurodegeneration 4/24/2000 T0012
Galvin, James E. Gene Expression Profile of Inclusion Bearing Neurons 4/24/2000 T0013
David Clifford, MD Mefloquine level in brain 12/10/2009 T0923
David L. Brody Development of an amyloid-beta oligomer assay 12/11/2009 T0924
Sophie Allauzen Novartis Protein Misfolding and Aggregation Assay Validation 12/17/2009 T0925
Pulliam, Joseph Validation of HFE mutation as a risk factor for Alzheimer's disease 10/10/2002 T0102
Goate, Alison Identification of the Chromosome 10 Alzheimer's Disease Susceptibility Locus 3/7/2001 T0103
Games, Dora Biochemical and morphological characterization of amyloid plaques in MCI and PDAPP transgenic mice 4/13/2001 T0109
William Klunk, MD PhD In Vivo PiB-PET Amyloid Imaging: Normals, MCI and Dementia 4/5/2009 T0907
Karl Herrup Alzheimer's neuropathology seen through the lens of cell cycle processes 4/14/2009 T0908
Powers, William Substrates of Mild Cognitive Impairment: Alzheimer's Disease and Vascular Neuropathologic Burden 4/25/2001 T0116
Holtzman, David M. Levels of Anti-amyloid-beta Antibodies in CSF of early AD patients 1/8/2001 T0118
Galvin, James E. The Role of Interstitial Neurons in Neurodegenerative Dementias 1/1/2001 T0121
Katherine B. Sims, M.D. Kufs Disease (Neuronal Ceroid Lipofuscinosis) 5/17/2009 T0909
John Kauwe, PhD Serum Biomarkers for Alzheimer's Disease 6/3/2009 T0910
Ruma Banerjee Redox and Ion Perturbations in Alzheimer's Disease 7/9/2009 T0911
D. German Pesticides and Alzheimer's Disease 8/5/2009 T0912
Holtzman, David M. % of Abeta species present in AD 9/21/2001 T0127
Jeffery W. Kelly Is the Kinetic Aggregation Assay suitable for Diagnosing ALazheimer's 12/23/2009 T0926
Emma Jones Functional Genetic Analysis: Mechanisms of Dementia in people with Down's syndrome 1/5/2010 T1001
Michael R Nichols Human Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease using an In Vitro Cellular Assay 1/18/2010 T1002
Cravchik, Anibal Case-control association study of genetic susceptibility factors for late onset Alzheimer's disease 11/21/2001 T0134
Herrup, Karl Cell cycle related neuronal death in early stage AD 12/28/2001 T0135
Dr David Holtzman The utility of the novel marker VILIP-1 in the diagnosis and prognosis of DAT 1/24/2010 T1003
Holtzman YKL-40, a Potential Endophenotype for Genetic Studies of Alzheimer's Disease 2/16/2010 T1004
Philip Verghese ApoE and Ab metabolism 2/22/2010 T1005
Mufson, Elliott aRNA profiling of NFT and non-NFT bearing CBF 12/5/2001 T0201
Holtzman, David M. Assessement of CSF sultatides as an AD biomarker 2/17/2002 T0204
Bowcock, Anne Genetic Risk Factors in Psoriasis 2/28/2002 T0205
Alison Goate, D.Phil Is Calcineurin CSF activity correlated with CSF phospho-tau levels and Calceneurin polymorphisms? 8/14/2009 T0913
Anne M. Fagan Comparison of xMAP vs Innotest Ab42 as markers of amyloid 9/10/2009 T0914
David M. Holtzman Targeted label-free LC-MS/MS analysis of CSF to identify biomarkers of AD 10/23/2009 T0915
Clark, Robert Gentics of Late-Onset Dementia in African-Americans 4/26/2002 T0212
Professor Kaj Blennow Targeted proteomics of cerebrospinal fluid amyloid-beta isoforms in Alzheimer's disease and controls 10/26/2009 T0918
Professor Kaj Blennow Targeted proteomics of cerebrospinal fluid amyloid-beta isoforms in Alzheimerís disease and controls 10/26/2009 T0917
Morris YKL-40, a Candidate Plasma Biomarker for Alzheimer Disease 10/26/2009 T0916
Todd, Richard Alternative Splicing of Nicotinic Acetylcholine Receptor Subunit Pre-mRNA in Dopaminergic Pathways 6/12/2002 T0213
Song, Sheng-Kwei Neuronal injury in AD brain detected using diffusion MRI 8/31/2002 T0221
Watson, Mark MGB1 / LPHB as a Diagnostic and Therapeutic Target for Human Breast Cancer 8/30/2002 T0222
David L. Brody Detection of amyloid-beta oligomers 3/19/2010 T1006
Alison Goate, D Phil Genentech Whole Exome Sequencing 3/22/2010 T1007
Joseph Rogers CR1 SNP association with Alzheimer's disease: authentication, validation, and mechanisms 4/7/2010 T1008
Liu, Connie N-terminally truncated abets species in early Down syndrome cases 12/2/2002 T0301
Galvin, James E. Dementia of the Parkinson type 1/16/2003 T0303
Dr Jin-Moo Lee VILIP-1is increased in the plasma of patients with ischemic stroke 10/28/2009 T0919
Xianlin Han Sulfatide/ceramide levels in non-demented individuals with neuropathological AD 4/2/2010 T1009
Elliott Mufson Rac1b expression in AD 5/10/2010 T1010
Ina Wanner Signature of astrocyte reactivity and injury in insult versus healthy brain cerebrospinal fluid, CSF 2/16/2012 T1212 To compare the CSF proteome of insult versus healthy brain in their astrocytic signature To measure levels of new astrocyte injury markers in insult versus healthy brain CSF
Dougherty Screening for antigens present in hypothalamic neurons 2/21/2012 T1213 Identify new antigens present in hypothalamic neurons
Stefan Irion Generation of iPSCs from FTD patient to study AD and ALS disease biology 2/29/2012 T1214 Generate iPSCs from FTD fibroblasts Differentiate iPSCs into neuronal cell types and glia Develop disease relevant assyas using differentiated cell types Identify disease specific phenotypes and disease mechanisms
Maria Isabel Behrens In search of common biological mechanisms for cancer and Alzheimer Disease 6/19/2010 T1011
Jaime Grutzendler Embolus extravasation: a novel mechanism of cerebral microvascular recanalization 6/23/2010 T1012
David Holtzman Neuroinflammation: potential role as a biomarker and treatment target for AD 6/24/2010 T1013
Perry, George Oxidative damage in mild cases of Alzheimer disease 2/20/2003 T0304
Reiman, Eric Neurogenomics of Alzheimer's Disease and Aging` 4/22/2003 T0305
Nigel J. Cairns Poly(ADP-ribose) accumulation in frontotemporal lobar degeneration with TDP proteinopathy 3/2/2012 T1215 To determine the role of PAR in the pathogenesis of FTLD-TDP
Luke Chamberlain Analysis of Biochemical Properties of Cysteine-String Protein Mutants in Kufsí Disease 3/26/2012 T1216 Analysis of Biochemical Properties of Cysteine-String Protein Mutants in Kufs‚Äô Disease
Stephen Chou Sample Request for Performance Testing of Ultrasensitive Immunoassay in Detecting Beta Amyloid in Pl 12/14/2012 T1232 Performance Testing of Ultrasensitive Immunoassay in Detecting Beta Amyloid in Plasma
Berislav V. Zlokovic CSF BIOMARKERS OF BLOOD-BRAIN BARRIER BREAKDOWN IN COGNITIVELY NORMAL AND ALZHEIMER'S INDIVIDUALS 12/24/2012 T1234 TO DETERMINE THE EFFECTS OF APOE GENOTYPE ON CSF MARKERS OF BBB BREAKDOWN IN COGNITIVELY NORMAL TO DETERMINE THE EFFECTS OF APOE GENOTYPE ON CSF MARKERS OF BBB BREAKDOWN IN MILD AND SEVERE AD
Berislav V Zlokovic Pericyte deficiency and blood-brain barrier breakdown in various Alzheimer’s disease APOE genotypes 12/24/2012 T1230 To determine the effects of APOE genotype on blood-brain barrier permeability in AD To determine the effects of APOE genotype on pericyte coverage and number in AD Investigate cell-specific distribution and levels of LRP-1 and MMP-9 in AD
David Holtzman Postmortem Receptor Autoradiography Study 7/21/2010 T1014
Vijay Sharma 99mTc-99m Labeled SPECT Agents for Imaging b-Amyloid in Alzheimer's Disease 7/26/2010 T1015
Karl Herrup The role of Cdk5 in Alzheimer's disease 8/4/2010 T1016
Hardy, John Expression studies examining novel loci involved in genetic susceptibility to neurologic disease 2/3/2003 T0306
Grupe, Andrew Functional validation of genes with LOAD 4/22/2003 T0309
Hardy, John Mutation screen in HDDD2 4/30/2003 T0310
Burns, Jeffrey Extrapyramidal Signs in Alzheimer Disease 5/2/2003 T0311
Drachman, David Enothelial changes in microvasculature undergoing neuronal loss and typical AD change 6/25/2003 T0313
Wilkins, Consuelo Vitamin D deficiency in normal aging and AD 6/20/2003 T0314
Bar-Or, David Potential diagnostic biomarkers for Alzheimer's disease 8/21/2003 T0317
Tu, Benjamin Pang-hsien Channel abnormality in Alzheimer's disease 8/19/2003 T0318
Tu, Benjamin Pang-hsien Alteration of calcineurin pathway in diffuse Lewy body disease 8/19/2003 T0319
Goate, Alison Genomic search for susceptibility to AD 9/8/2003 T0324
Cruchaga 6/8/2011 T1108 to identify the causative variant of Kufs' disease
Pastor, Pablo Analysis of the 17q21 region in familial fronto-temporal dementia and in sporadic tauopathies 9/9/2003 T0326
Pastor, Pablo Genetic analysis of the 17q21 region in familial FTD and in sporadic tauopathies 10/13/2003 T0326A
Pastor, Pablo genetic analysis of the 17q21 region in familial frontotemporal dementia and in sporadic tauopathies 4/2/2004 T0326B
Goate, Alison National Cell Repository for Alzheimer's Disease 8/25/2002 T0327
Loeffler, David Significance of Complement Activation in the Progression of Parkinson's Disease 10/7/2003 T0328
Sun, Grace Proteins and gene expression in AD 10/17/2003 T0329
Sun, Grace Proteins and gene expression in AD 10/17/2003 T0330
Binder, Ellen Rehabilitation Intensification Post Hip Fracture 10/24/2003 T0331
Funck, Theodor Diagnostics of Neurodegenerative Disorders by Ultrasonic Investigations 1/27/2004 T0402
Mancuso, David Calcium Independent Phospholipases A2 in Alzheimer's Disease 2/4/2004 T0404
Han, Seol-Heui Are Aberrant Cell-cycle Pathways linked to alpha-Synuclein -induced Neurodegeneration? 2/10/2004 T0405
Han, Xianlin Postmortem CSF analysis 3/30/2004 T0411
Csernansky, John G. Correlation of Plasma Cortisol and Clinical Progression in Early DAT 4/14/2004 T0414
Holtzman, David M. Identification of biomarkers for Alzheimerís disease using proteomics approaches 5/23/2004 T0419
Baird, Alison E Stroke Genomics 6/1/2004 T0421
Cristina Tan Hehir Fluorophore that selectively binds soluble oligomers 2/14/2011 T1102 To Investigate the value of measuring different forms of Aβ species in human brain tissue
Illarion Turko Role of Oxysterols in Alzheimerís Disease 2/22/2011 T1103 Absolute quantification of cholesterol-metabolizing cytochrome P450s Absolute quantification of sulfotransferases Absolute quantification of proteins that are targets of oxysterol action
Michael Shelanski/John Crary 3/22/2011 T1105 To identify biochemical alterations in tangle-only dementia To identify genetic variants in tangle only dementia
Timothy M. Miller Examining miRNAs in AD Patient CSF 4/25/2011 T1106 Determine feasibility of measuring miRNAs in human CSF in AD vs. Control Determine whether miRNA 155 is increased in AD patients vs. Control
Tapan Kumar Khan Activated Erk1 and Erk2 in the cerebrospinal fluid of Alzheimer’s disease patients 8/26/2011 T1109 Measure Erk phosphorylation in CSF. Determine the pathologic relevance of Erk phosphorylation in AD Assess other kinases as potential CSF biomarkers of AD
Carlos Cruchaga Identification of genetic variants associated with cerebrospinal fluid granulin levels 12/16/2010 T1020 To identify genetic variants associated with CSF GRN levels through a genome-wide association study
Jeffrey Zacks Encoding and remembering events across the lifespan 12/17/2010 T1021 Does event segmentation predict event memory beyond that accounted for by clinical dementia status? Is the segmentation-memory relationship mediated by changes in the prefrontal or posterior cortex? Does event segmentation predict genetic indicators of Alzheimer's disease (e.g., APOE4 status)?
Perrin, Richard Novel CSF Biomarkers in Dominantly Inherited and Sporadic AD 9/30/2014 T1417 Integrate novel CSF biomarkers into the timecourse of established AD features Compare CSF biomarkers of Dominantly Inherited and Sporadic AD
Balota, Dave A. Genetic, Personality, & Attention Factors in Aging & DAT 6/7/2004 T0422
Goate, Alison Molecular Genetics of Familial Dementia 7/30/2004 T0427
Roe, Catherine Gamma-Secretase Activity as a Modulator of Cancer and AD Risk - A Genetic Test of this Hypothesis 7/27/2004 T0428
Schulman, Howard Discovery of Biomarkers for Alzheimer's Disease 10/18/2004 T0433
Lee, Jin-Moo Matrix metalloproteinases and Alzheimer's Disease 12/2/2004 T0501
Lee, Jin-Moo Amyloid-beta degradation in Alzheimer's Disease 12/2/2004 T0503
Demattos, Ronald To study the protein profile differences between Alzheimerís disease patients and non-AD age-matched controls. 12/17/2004 T0506
Holtzman, David M. Effects of ABCA1 on apoE levels in the Central Nervous System 1/5/2005 T0507
Wolozin, Benjamin Effects of Statins on Human Brain Pathology 1/26/2005 T0507
Sharma, Vijay Imaging b-Amyloid Plaques in the Brain 2/8/2005 T0510
Grammas, Paula Is there a link between Alzheimer's and Atherosclerosis? 6/17/2005 T0517
Goate, Alison Discovery of causative gene underlying Frontotemporal Dementia with ubiquitine-positive neuronal inclusions on chromosome 17 8/1/2005 T0520
Nowotny, Petra Is allele specific expression a risk factor for late onset AD? 8/10/2005 T0522
Mucke, Lennart Molecular markers for Alzheimer disease cognitive impairment 8/29/2005 T0525
Snider, B. Joy Protein degradation systems in early Alzheimer's disease 10/13/2005 T0527
Wyss-Coray The plasma proteome of secreted signaling proteins in people with pathological biomarkers for AD 10/16/2011 T1110 To measure the plasma communicome associated with amyloid-positivity in cognitively normal individua To discover biological pathways associated with amyloid-positivity in cognitively normals
William Z. Suo New strategy to fight selective cholinergic neuronal loss in Alzheimerís disease 1/28/2011 T1101 Determine if membrane G protein-coupled receptor kinase-5 (GRK5) deficiency is a feature of AD Look for footprints of presynaptic M2 hyperactivity in basal forebrain cholinergic neurons in AD
Jason Hassenstab Obesity, Insulin Sensitivity, and Functional Connectivity in Normal Aging 2/28/2011 T1104 Do PIB- CDR 0's with obesity and insulin resistance perform poorly on memory and exec. function? Do PIB- CDR 0's with obesity and insulin resistance have reduced functional connectivity? Do PIB- CDR 0's with obesity and insulin resistance have lower brain volumes/cortical thickness?
Oscar Alzate Biomarkers of Alzheimer's disease 10/18/2011 T1111 To identify differential regulation of protein isoforms of APO family of proteins
Kelly R. Bales in collaboration with David Holtzman 5HT4 expression survey 5/6/2011 T1107 Determine level of 5HT4 mRNA (including splice variants) in brain tissue from CDR 0, 0.5, 1 and >1 Determine the level of 5HT4 protein in brain tissue from CDR 0, 0.5, 1 and >1 Determine the level of 5HT4 agonist binding in brain tissue from CDR 0, 0.5, 1 and >1
Paul Kotzbauer Neurochemical Correlates of Cognitive Phenotypes of Parkinson Disease 10/20/2011 T1112 To determine whether regional neurotransmitter deficits correlate with cognitive phenotypes in PDe
Stephen M. Strittmatter Measuring Levels of Amyloid Beta Oligomers Capable of PrP Interaction 4/22/2012 T1217 Use Novel Assay to Measure PrP-Interacting Aß Oligomers in AD versus Control Samples
G. William Rebeck Early effects of APOE genotype on brain function 4/23/2012 T1218 Determine if APOE genotype affects CSF levels of neuronal metabolites
Yan Zhang Ankyrin G levels in AD tissues 5/15/2012 T1219 The levels of Ankyrin G will be measured in control and AD tissues To confirm if Ankyrin G is downregulated in AD brains Search for mechanism of Ankyrin G downregulation in AD
Marc I. Diamond Identification of novel anti-tau antibodies capable of blocking tau propagation 2/14/2013 T1304 To test whether novel anti-tau antibodies can block tau seeding induced by human brain lysate
RJ Bateman Bioanalytical Assay Method Validation for Alzheimer?s Disease Clinical Trials 10/14/2014 T1418 To create pools of CSF to be used to conduct full bioanalytical method validation on the INNO-BIA AlzBio3 assay for use in clinical trials
Jose Bras Role of Genomic variability in Lewy Body dementia 5/29/2012 T1220 Identification of genetic variability conferring risk for DLB
Anja Schneider/Andre Fischer Genome-wide profiling of CSF miRNA expression in antecedent AD using next generatio 6/15/2012 T1221 next generation deep sequencing of CSF miRNAome Identification of antecedent miRNA biomarkers to predict later AD Identify longitudinal changes in CSF miRNAome accompagnying preclinical AD
Elliott Mufson CSF proNGF: a putative biomarker for Alzheimer’s disease 6/18/2012 T1222 We will test whether CSF levels of proNGF are predicitve or prodromal AD. Test whether CSF proNGF levels improve the diagnostic accuracy of CSF tau/Abeta Test whether CSF proNGF levels correlate with antemortem measures of cognitive decline.
Stephen is the PI of the UL grant; Wingo is the PI of the URC/ASCTI grant Autosomal Recessive Causes of Early-onset Alzheimer's Disease 6/22/2012 T1223 Our overarching aim is to test the hypothesis that early-onset Alzheimer’s disease (AD) has autosoma
Alison Goate/Carlos Cruchaga Identification of rare variants implicated on Alzheimer’s Disease 8/1/2012 T1224 Identification of rare variants implicated on Alzheimer’s Disease
Pickering-Brown, Stuart Genome wide association in tau -ve FTD 3/2/2006 T0609
Lee, Jin-Moo Serum Aβ levels and White Matter Lesions 3/24/2006 T0611
hu. helen biomarker for alzheimer's disease 5/1/2006 T0613
Goate, Alison Variation in tau expression and risk for PSP 5/5/2006 T0614
Richards, Anna Mapping the gene for cerebroretinal vasculopathy 6/9/2006 T0615
Zlokovic, Berislav sLRP Levels in Plasma of Alzheimer's Disease and Control Subjects 6/28/2006 T0616
Zhang, Weixiong Microarray gene expression profiling of late onset AD 8/28/2006 T0621
Fagan, Anne Validation of XMAP technology for measurement of Ab42, tau and ptau181 in plasma 10/30/2006 T0624
Wyss-Coray, Tony Plasma proteomic markers associated with cognitive dysfunction 11/4/2006 T0625
Wang, Rong Biomarkers for Early Detection of Alzheimer's Disease 11/28/2006 T0626
Goate, Alison Progranulin in CSF 11/16/2006 T0627
Penzes, Peter Expression of postcynaptic signaling proteins in cortical tissue of Alzheimer's patients 12/15/2006 T0701
GANDY, SAM Interdisciplinary Approach to Alzheimer Drug Discovery 12/16/2006 T0702
Burke, James NOS2 Promoter Polymorphisms as Risk Factors in Dementia 1/3/2007 T0706
Shaw, Leslie M Validation of a multiplex immunoassay for CSF Biomarkers 2/9/2007 T0707
Gambetti, Pierluigi Pathogenetic mechanism of prion diseases 2/16/2007 T0709
Cairns, Nigel Determination of fibril size in inclusions of FTLD-U 2/20/2007 T0711
Cairns, Nigel TDP-43 Proteinopathy: Discovering Causes of Clinical and Neuropathological Heterogeneity 4/10/2007 T0714
Abraham, Carmela The function of Klotho in the normal and aging brain 3/6/2007 T0716
Goldstein, Lee, E. Alzheimer's disease-linked Abeta pathology in the lens 8/22/2007 T0726
Nowotny, Petra Is allele specific expression a risk factor for late-onset Alzheimer's disease? 9/5/2007 T0727
Gitcho, Michael TDP-43 gene expression 9/21/2007 T0728
Van Deerlin, Vivianna Genome wide association study of frontotemporal dementia +/- motor neuron disease with TDP-43 pathology or progranuli mutations 11/1/2007 T0732
GANDY, SAM CSF ALCADEIN FRAGMENT PATTERN AS A BIOMARKER FOR AD 11/16/2007 T0801
Gao, Zhiyong Study of Alzheimer's disease using in vitro methods 11/27/2007 T0803
Lee, Jin-Moo VLP-1 as a biomarker for neuronal death in Alzheimerís Disease 12/4/2007 T0805
Montine, Thomas Alzheimer's Disease Genetics Consortium 12/24/2007 T0806
Walsh, Dominic A oligomers in the aged and diseased human brain 1/26/2008 T0809
Holtzman, David M. Assessment of apoE isoform level by mass spectrometry 2/22/2008 T0815
Sun, Grace Immunohistochemistry identification of cPLA2 and COXII in control and AD brain 6/18/1999 T9901
Sun, Grace Expression of metabotropic glutamate receptor 5 and 7 mRNAs in AD brain 6/18/1999 T9902
Kido, Daniel Microhemorrrhages in the Elderly 7/12/1999 T9903
Surguchov, Andrei Sera and CSF Synoretin in AD 3/8/1999 T9907
Smith, Mark A. Oxidative Damage via Mitochondria-derived Free Radical Accumulation 6/7/1999 T9908
Kennard, Malcolm p97 3/8/1999 T9909
Finch, Caleb E. (Tuck) Characterization of complement factors and their association with A-beta deposits 9/7/1999 T9912
Huntington Potter Effect of immunotherapy on ACT and apoE binding to AD amyloid 11/19/2010 T1019 Determine whether anti-amyloid immunotherapy changes level of antichymotyrpsin in plaques Determine whether anti-amyloid immunotherapy changes level of apoE in plaques
Tim West, PhD Test Performance of a Novel Multiplex Assay to Quantify AD Biomarkers Within Cerebrospinal Fluid 11/1/2011 T1113 Correlate concentrations measured by ELISA and SISAQ for Tau and Aő≤ 40 and 42 Compare the reproducibility of ELISA measures with SISAQ measures Measure how well SISAQ measures distinguish individuals with disease pathology from those without
Dr. John Hardy Whole-exome sequencing of autopsy confirmed samples to identify rare variants implicated on AD 11/16/2011 T1201 The aim of this study is to identify rare alleles of large effects on risk for Alzheimer’s Disease
Randall J Bateman Amyloid-Beta Metabolism in Familial Adult Children Study 11/30/2011 T1203 Measure production rates of Amyloid-beta protein isoforms in mutation carriers
Robert Siman A panel of neurodegeneration biomarkers for Alzheimer's progression 12/7/2011 T1204 Evaluate CSF levels of 7 neurodegeneration biomarkers in relation to neurocognitive status Compare CSF neurodegeneration biomarker levels with biomarker evidence for AD neuropathology
Joel Perlmutter, MD Use of PIB Imaging to Evaluate Dementia Subtypes in People with Parkinson Disease 12/8/2011 T1205 To determine whether or not Alzheimer and Lewy body dementia have different cortical PIB uptake To determine whether or not PIB uptake correlates with the presence of symptoms in AD and Lewy body. To determine whether or not Amyloid Beta, Tau and Alpha Synuclein are present in the spinal fluid. To determine whether elevated PIB uptake identifes a population most at risk for dementia.
Stephen Graves, John Kauwe Serum Biomarkers for Alzheimer’s disease 12/13/2011 T1206 To validate putative serum biomarkers in an independent series.
Carlos Cruchaga, Celeste Karch Identification of rare variants implicated on Alzheimer’s Disease 8/13/2012 T1225 To identify genes deferentially expressed in AD brains compared to controls To identify proteins with different levels in AD brains compared to controls To identify genetic variants associated with gene expression
John C. Morris/Jungsu Kim MicroRNA biomarkers for early detection of Alzheimer's disease 9/6/2012 T1226 Identification of cerebrospinal fluid miRNA biomarkers for early detection of AD Identification of plasma miRNA biomarkers for early detection of AD
G. William Rebeck Early Effects of APOE genotype on brain function 10/12/2012 T1218-A Identify CSF biomarkers of AD risk Measure levels of neurotransmitters in CSF
Holly D. Soares Development of IVD CSF AB42 and Tau Assays 10/12/2012 T1227 Aim 1: To define normative ranges in cognitively normal individuals who have remained cognitively n Aim 2: To define assay specific cutpoints for cognitively impaired individuals at risk of progressi
Steven Schreiber, MD Histone deacetylase activity in Alzheimer’s disease 10/30/2012 - To evaluate HDAC activity and abundance in CSF from AD, MCI, age-matched controls To determine whether there is a correlation between CSF HDAC activity and clinical features
TERESA GOMEZ-ISLA Dissecting molecular mechanisms involved in human brain resilience to Alzheimer’s pathology 10/31/2012 T1228 Are some human brains resistant to AD pathology (amyloid plaques and neurofibrillary tangles)? What are the neuroprotective mechanisms involved? Is the Abeta/tau phenotype what determines structural damage and impaired cognition in AD?
Carlos Cruchaga Identification of genetic variants associated with cerebrospinal fluid granulin levels (Amendment) 12/27/2011 T1209 To identify genetic variants associated with CSF GRN levels through a genome-wide association study
Dr. John Hardy Genome wide association studies (GWAS) for Frontotemporal-dementia (FTD). 12/30/2011 T1210 Identification of common variants associated with FTD
Brody Assessment of amyloid-beta oligomers with a novel assay 1/13/2012 T1211 To assess amyloid-beta oligomers in additional patients and additional brain regions
Kenneth S. Kosik Gene expression analysis of MAPT mutation carriers 4/9/2014 T1407 Transcriptome sequencing for RNA obtained from neurons derived from iPS patients Comparison of differentially expressed genes compared to human healthy lines and tissue miRNA profiling of these samples as in 1 Determination of coexpression modules associated with the MAPT mutations
Ronald DeMattos Analyses of Full-Length, Truncated, and Modified Aő≤ Species across the Alzheimer‚Äôs Disease Spectrum 4/14/2014 T1408 Quantify the multiple forms of deposited Aő≤ that arise throughout the disease cascade (from normal through moderate stages of disease)
Nikolaos Robakis Correlation of microRNA and protein expression in AD brains 11/10/2012 T1229 Levels of neuronal microRNAs and target proteins, including PEA-15 and EphB2 in AD brains.
Kenneth Kosik Gene expression analysis of MAPT A152T mutation carriers 12/5/2012 T1231 Transcriptome sequencing of RNA obtained from patients’ samples. Comparison of differentially express genes compared to human healthy tissue.
Carlos Cruchga Identification of novel CSF endophenotypes and genetic variants for AD by Mendelian Randomization 4/19/2013 T1308 To analyze whether cerebrospinal fluid CLU, APOE and ACE levels are informative AD endophenotypes
JC Morris Internal Controls and ISR Program for use in clinical trials 6/6/2013 T1309 To create pools of CSF to be used for Incurred Sample Reanalysis (ISR) in clinical trials
David W. Colby Detection and Structural Analysis of Tau Protein in Neurodegenerative Disease 6/4/2013 T1310 Detect misfolded tau in Alzheimers Disease CSF by Amyloid Seeding Assay Analysis of in vitro structural propagation of tau conformers from AD CSF
David Holtzman The effects of TREM2 variants on plaque-associated microglia in Alzheimer's disease 10/15/2014 T1419 Assess the size, number, and percent area covered by plaque associated microglia in carriers and non-carriers of TREM2 variants associated with Alzheimer's disease
Lee, Jin-Moo Serum or CSF marker for brain injury 10/18/2005 T0528
Yang, John Yuan-Han Expression of angiotensin 1-converting enzyme gene polymorphism in very mild demented and normal cognitive individuals 10/21/2005 T0529
Opiteck, Gregory J. BIOMARKER DISCOVERY IN BLOOD PLASMA FROM ALZHEIMER'S PATIENTS 10/24/2005 T0530
Geschwind, Daniel Sequencing of FTD candidate gene 11/17/2005 T0534
Morris, John C. Genetic Associations with Alzheimer-free Survival 12/21/2005 T0601
Goate, Alison Functional studies of variants in the muscarinic acetylcholine receptor M2 (CHRM2) that demonstrate association with alcohol dependence, depression and related phenotypes 2/21/2006 T0604
Nowotny, Petra Is allele specific expression a risk factor for late onset AD? 2/23/2006 T0606
Anne Fagan and Hideaki Bujo Soluble LR11 (sLR11) as a potential CSF biomarker of AD 12/20/2011 T1207 Test ability of CSF sLR11 to distinguish cognitively normal individuals from DAT Investigation the relationship between sLR11 and Ab42 Future: utility of sLR11 as a prognostic biomarker of future cognitive decline in CDR 0
Marc Diamond Testing for tau aggregate seeding activity in CSF as a possible AD biomarker 12/20/2011 T1208 Test whether a novel tissue culture assay can detect tau aggregate seeds specifically in AD samples
Matthew Harms Tissue heterogeneity of the C9ORF72 expansion in carriers 12/17/2012 T1233 Characterize differences the C9 repeat expansion between tissue types (brain vs non-brain) Characterize differences the C9 repeat expansion between brain regions Correlate tissue expansion sizes with C9 expression levels Correlate tissue expansion sizes with neuropathological features
Alison Goate Defining the mechanisms of AD pathogenesis in human IPSC-derived neurons 1/17/2013 T1301 To measure the influence of pathogenic FAD mutations on APP and tau metabolism in human neurons
Philip B. Verghese Amendment to ‚ÄúApolipoprotein E Isoforms and Aő≤ Metabolism (T1005) 2/6/2013 T1005-A Characterize the CNS apoE isoform-associated proteome and lipidome in normal and AD subjects Determine how lipids and proteins of apoE isoforms modulate apoE functions
David L. Brody PrP-interacting Aß oligomers in Human Cortical Lysates 2/7/2013 T1302 Determine the correlation between PrP interacting amyloid beta oligomers and clinical symptoms.
Chadwick Hales RNA splicing dysfunction in familial AD. 2/13/2013 T1303 To study RNA splicing in familial AD cell lines, IPS cells, and derived neurons.
John Morris sLR11 as a potential CSF biomarker of AD (amendment to T1207) 3/25/2013 T1207-A to characterize the staining distribution of LR11 in control, AD and non-AD brain
Vijay Sharma Novel PET Tracer for Imaging Amyloid ő≤ in the Brain 4/1/2013 T1305 To determine specificity of the agent for amyloid ő≤ compared to other biomarkers
Sidney Strickland Investigation of a prothrombotic state in AD patient plasma 4/11/2013 T1306 Determine if AD patient plasma exhibits accelerated clot formation compared to control plasma Determine if AD patient plasma exhibits accelerated and increased thrombin generation
TAE SUNG LIM Dementia of the Alzheimer’s type in Autopsy-Proven Corticobasal Degeneration 4/13/2013 T1307 to compare the longitudinal course of clinical and psychometric features of 18 CBD and 18 matched AD to evaluate the co-existence of other neurodegenerative proteinopathies using immunohistochemistry to evaluate the contribution of other neurodegenerative proteinopathies to the clinical features.
Celeste Karch Identification of Common Targets in Human MAPT Mutation Carriers 10/18/2014 T1420 To define the pathways disrupted in human brain tissue and human neurons from MAPT mutation carriers. To define the pathways disrupted in human CSF and media from human neurons from MAPT mutation carriers. To define the tau-specific modifications in human CSF, brain tissue, and neurons from MAPT mutation carriers.
David Brody Detailed Characterization of Amyloid-beta Oligomers in Human Alzheimer Disease Brains 6/7/2013 T1311 To purify multiple forms of Aő≤ oligomers from water-soluble lysates of human AD brains
Rebeck GW Lipoprotein metabolism in human CSF depending on AD pathology and apoE genotype. 6/24/2013 T1312 Analysis of apoE fragments and dimers in CSF samples of AD patients and controls Investigate influence of genotype on apoE fragments and apoE dimers in human CSF
Richard Perrin CSF Biomarker Discovery for AD vs PDD 7/1/2013 T1313 To compare CSF Ab42 and CSF tau expression profiles and their cutpoints for PIB positive vs. PIB neg To compare CSF Ab42 and CSF tau expression across the following groups: CDR 0 (normal vs PD), CDR 0. To compare ‚Äėnovel‚Äô CSF biomarkers between Knight ADRC and WU PD cohorts, categorized by CDR and 'AD To compare many ‚Äėnovel‚Äô CSF biomarkers across different platforms: Rules Based Medicine vs. MSD vs (
Kauwe Association between Toxoplasma gondii infection and Alzheimer’s disease 8/29/2013 T1314 To determine the prevalence of latent infection with T. gondii in AD cases vs. non-demented To determine the relationship between T. gondii and cognitive outcome in AD and in normal aging
Laila Abdullah Use of lipidomics to identify biomarkers of mild cognitive impairment and Alzheimer’s disease 9/23/2013 T1315 To determine if CSF lipid profiles correlate with PIB imaging-based brain amyloid burden To determine if lipid profiles can diagnostically differentiate MCI and AD patients from controls To determine if lipid profiles can enhance the accuracy of PIB imaging in diagnosing MCI/AD
Jin Moo Lee ICH GWAS 10/2/2013 T1316 GWAS analysis for primary hemorrhage
Francis Hane 10/28/2014 1422 Quantifying binding of affinity tags to amyloid oligomers
Dr. Rademakers Progranulin: mutation and regulation in neurodegenerative disease 5/30/2014 T1410 To identify genetic modifiers of symptom onset and/or presentation in GRN mutation carriers using a genome-wide association study (GWAS) To identify genetic modifiers of symptom onset and/or presentation in GRN mutation carriers using an exome-sequencing approach
Randall J Bateman Optimization of ApoE Detection by LC/SRM-MS 6/11/2014 T1411 Improve sample processing for absolute quantitation of ApoE isoforms in human cortex samples
Samuil Umansky Alzheimer's disease detection and monitoring by analysis of circulating brain-enriched microRNA 10/8/2013 T1317 To determine how early MCI can be detected by analysis of previously found plasma miRNA biomarkers To validate pre-selected miRNA biomarkers for differentiating AD and non-AD brain pathollogies To validate pre-selected miRNA biomarkers for monitoring AD progression from early stage to dementia
Makoto Ishii Altered leptin signaling in Alzheimer's disease 10/14/2013 T1318 To determine if alterations in leptin signaling are found in earliest stages of Alzheimer's disease
Erin H. Norris Pathological consequences of hypertension in Alzheimer's disease 10/28/2014 T1421 Identify molecular changes at the neurovascular unit in hypertensive humans with AD
David Holtzman : Synuclein seed detection in brains of patients with synucleinopathies 10/15/2013 T1319 Detect synuclein seeds in brain tissue of different synucleinopathies Determine if there are unique conformers of synuclein in the different synucleinopathies Determine if there is regional specificity of synuclein conformers
Sidney Strcikland Identification of a Plasmin-Resistant Fibrin Fragment as a Biomarker for Alzheimer’s disease 10/14/2013 T1320 Determine a level of plasmin-resistant fibrin fragment in CSF from AD patients The relationship between a level of Fibrin Fragment and pathological characteristics of AD patients
Joel Kramer Disease-free Aging Control Group for Tau Consortium Genetic Studies 10/16/2013 T1321 provide DNA from functionally normal controls without family history of neurodegenerative disease
Marc I. Diamond Characterizing tau aggregate species via structural mapping 10/23/2013 T1322 Cluster tauopathy patients in clinically meaningful ways via structural mapping of tau aggregates. Determine if disease progression rates are influenced by tau aggregate protein structure. Determine if tau aggregate protein structure is consistent between brain regions.
Langford importance of PINCH protein levels in CSF in AD 11/8/2013 T1323 do levels of PINCH protein in CSF correspond to neurocognitive status in AD do levels of PINCH protein in CSF correspond to immune system functional status
Yueming Li regulation and function of ő≥-secretase 12/30/2013 T1324 Determine the function of g-secretase in Sporadic Alzheimer disease
Goate/Cruchaga Whole-exome sequencing of early-onset samples to identify rare variants implicated on Alzheimer’s Disease. 1/22/2014 T1401 To identify novel genes and coding variants implicated on Alzheimer's disease risk
Manuel Sarasa The kinetics of the plasma Aő≤ biomarkers (Aő≤42, Aő≤40) in the Adult Children Study (ACS). 2/17/2014 T1402 To measure the levels of Aő≤ plasma markers (DA and RP for Aő≤42, Aő≤40) in the ACS cohort. To identify which demographic (age, family history, ApoE genotype, sex, years of education) hematological (hematocrit, blood cell counts, if available in ACS database) and serum biochemical covariables (creatinine, homocysteine, urea, uric acid, hemoglobin, and serum total proteins, if available Alternatively, these analysis could be performed at Araclon‚Äôs lab if a frozen serum sample would be provided) are significantly associated with the levels of Aő≤ plasma markers in the ACS cohort. Those statistical significant correlates should be included as potential confounding factors in the multi To describe the progression of plasma Aő≤ biomarkers over time in each subject and the variation in the trajectories between subjects in a model adjusted for the relevant confounding factors.
Kukull (Penn) Validation of non-amyloid, non-Tau CSF biomarkers of Alzheimer’s disease 2/18/2014 T1403 Aim 1: We will validate 12 non-amyloid, non-Tau CSF biomarkers of AD in samples from subjects with normal cognition, AD, and non-AD dementias, longitudinally followed at the three Centers (WU, Penn, Emory). Aim 2: We will identify non-amyloid, non-Tau biomarkers suitable as staging and progression biomarkers in AD, evaluate their specificity for AD vs non-AD dementias, and evaluate the technical variability of the relevant assays across three independent Centers.
Mathew Blurton-Jones 2/18/2014 T1404 Generation, gene-correction, and microglial differentiation of iPSC clones from patients with the AD-associated R47H TREM2 mutation. Do mutations in TREM2 alter the activation state, migration, or phagocytic activity of human microglia? Do TREM2 mutations alter microglial function and modulate Abeta and tau pathology in vivo?
Eric J Kremer Screen for a biomarker in early satges of late-onset AD 2/21/2014 T1405 Screen CSF from AD patients for the presence of a cleaved presynaptic protein diminished in early satges of late onset AD Screen AD SGZ for the presence of a cell adhesion molecule diminished in early satges of late onset AD
Cruchaga/Sands Identification and functional characterization of the genetic variant causing Kufs’ disease with early dementia in a family with an autosomal dominant inheritance (Amendment) 2/21/2014 T1108-A to identify the causative variant of Kufs' disease to characterize the causative mutations
Dr. Tom Montine : Neuropathological assessments of fibrillar amyloid burden in APOE e4 carriers and non-carriers with the clinical diagnosis of Alzheimer's dementia 3/13/2014 T1406 . In this study, NACC data will be used to compare the proportions of expired brain donors with the clinical diagnosis of Alzheimer's dementia in terms of their fibrillar amyloid burden and other neuropathologic features
Ina B. Wanner Astroglia protein release as biofluid markers of neurodegeneration 4/21/2014 T1212-A Determine significance of elevated astroglia marker protein release between Control and TBI patients' CSF and plasma Pilot study to determine whether astrocyte release markers are elevated in AD versus Control CSF and plasma
Gregory J. Zipfel STAT3 activation and neurovascular dysfunction in Alzheimer’s disease 4/22/2014 T1409 We plan to study the phosphorylation and acetylation of STAT3 in the blood vessels isolated from human AD brains
Laura Piccio and Carlos Cruchaga TREM2 as a key player and a potential biomarker in Alzheimer’s disease. 4/28/2014 - To determine whether the CSF and serum levels of sTREM2 are associated with clinical AD and/or with a TREM2-variant carrier status.
Vijay Sharma PET Tracers for Detection of AD 5/15/2014 T1305-A Assess senstivity of PET tracers to detect diffuse and fibrillar Ab-plaques in AD
Jennifer Furman Tau Seeding Activity in Alzheimer's Disease 6/16/2014 T1412 Monitor seeding activity through AD disease progression Test if seeding activity manifests early in tau progression
Alison Goate The role of phospholipase D3 in the lysosome 7/24/2014 T1413 To determine whether PLD3 is detectable in lysosomes from human brain tissue
Masaaki Matsuoka Calmodulin-like skin protein in Alzheimer's disease 8/11/2014 T1415 Calmodulin-like skin protein in the pathogenesis of Alzheimer's disease Diagnostic value of CLSP in Alzheimer's disease
William G. Fairbrother Analysis of Defective pre-mRNA Splicing of Disease-causing PSEN1 Genetic Variants in Biological Samples from Alzheimer's Disease Patients 8/13/2014 T1414 Fairbrother Validate results obtained using a high-throughput splicing assay with respect to causal PSEN1 mutations in biological samples, such as postmortem brain samples and/or blood, from Alzheimer's disease patients.
Piotr Lewczuk Correlation of the Aβ PET uptake and the CSF Aβ42/40 ratio 8/18/2014 T1416 Lewczuk To determine if the CSF Aβ42/40 concentration ratio correlates better with the PIB-PET data than the Aβ1-42 concentration alone.
Randall Bateman Human CNS Apoliproprotein E Isoform Production and Clearance 4/9/2008 S0819
John Morris Phase III Elan Passive Immunization with ApoE 4 non-carriers 4/9/2008 S0818
Lenze Escitalopram and cognitive behavioral therapy for the maintenance of response in late life GAD 6/27/2008 S0820
Dr. Chris Rosnick Interrelationship among intrusive thinking, personality and cognition in aging and in early stage AD 10/15/2008 S0821
John Morris Phase III Elan Passive Immunization with ApoE 4 carriers 4/9/2008 S0817
Suping Bao Perceptions about End-of-Life Issues in Patients with Dementia of the Alzheimer Type 12/10/2008 S0822
James Galvin Informant assessment of attention 12/15/2008 S0823
S. Duntley Preclinical executive dysfunction in idiopathic REM sleep behavior disorder 1/9/2009 S0901
David M. Holtzman Neuroinflammation: Potential role as biomarker and treatment target for AD 2/13/2009 S0902
Nupur Ghoshal, MD, PhD BMS-708163 in Treatment of Patients with Prodromal AD 4/10/2009 S0904
Elizabeth Mulligan Grief Among Dementia Caregivers: A Comparison of Two Assessment Systems 4/26/2009 S0905
Denise Head Brain Aging, Stress and Exercise 4/29/2009 S0906
James Galvin Art, Alzheimer and Aesthetics in the 21st Century 5/22/2009 S0907
Heidi Franz-Hoyt The Use of Social Support by Spouses of Alzheimer's Patients to Improve Communication 6/5/2009 S0908
Carolyn Dufault/Martha Storandt The Measurement of Visual Attention in Healthy Aging and Alzheimer's Disease 6/26/2009 S0909
James Galvin Phase IIa, Randomized, third-Party Unblinded, Long-Term Extension Study of ACC-001 with and without 6/30/2009 S0910
Thomas M. Meuser Personal Meanings & Emotions in Life Space Mobility 8/18/2009 S0911
Eric J. Lenze, MD Incomplete Response in Late-Life Depression: Getting to Remission 10/19/2009 S0913
Dr lesley Greene Effects of environmental pollutants on Alzheimer's disese 11/15/2009 S0914
Beau Ances Effects of donepezil on regional cerebral perfusion and cognition 11/22/2009 S0915
David Carr A Phase 3 Extension of the ELN115727 301/302 Study 11/30/2009 S0916
John Morris, MD Alzheimer's Disease Neuroimaging Initiative-Grand Opportunity 2/5/2010 S1001
Binder/McDaniel Combining exercise and cognitive training to improve everyday function 2/8/2010 S1002
David B. Carr,MD Fitness to Drive in Older Adults 2/11/2010 S1003
B. Joy Snider Protocol H6L-MC-LFBF-Open-Label Extension for Alzheimer's Disease Patients Who Complete Semagacestat 2/12/2010 S1004
B. Joy Snider Protocol H8A-MC-LZAT Plasma Amyloid Beta Species after a Single Solanezumab Infusion in Nondemented 2/16/2010 S1005
Jonathan L. Haines, Ph.D Genetic Epidemiology of Alzheimer's Disease in African Americans 2/22/2010 S1006
David M. Holtzman Sleep and amyloid-beta 6/16/2010 S1007
Alyse Firtel/Mitchell Sommers Evaluating Auditory-Visual Speech Perception in Individuals diagnosed with Alzheimer's Disease 8/11/2010 S1008
David A. Balota Testing the Utility of Implementation Intentions in the Very Mildly Demented 8/20/2010 S1009
Denise Head Spatial Navigation Skills in Alzheimer's Disease 10/24/2010 S1010 compare navigational skills between nondemented and very mild AD groups compare navigational skills between APOE e4+ and e4- groups compare navigational skills between PIB+ and PIB- CDR=0 groups examine associations between navigational skills and brain volumes
Mike Weiner (Awarded NIH Grant) Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2) 10/26/2010 S1011 Determine and define biomarkers which best predit future cognitive decline. Determine biomarkers that can serve as outcome measures to quantify the rate of disease progression. Define biomarker measures that can be used to develop the most effective clinical trial scenarios. Validate diagnoses and imaging/biomarker measures through neuropath exam of ADNI participants.
Mark E. Wheeler Neural mechanisms of perceptual memory decisions in mild cognitive impairment 10/28/2010 S1012 Test whether parietal integrity affects performance in perceptual choice and recall tasks Identify neural signals related to the integration of evidence over time. Determine whether neural integration signals are affected in early stages of dementia
Morris/Benzinger Quantitative PET Imaging without Arterial Blood Sampling 11/1/2010 S1013 To investigate the feasibility of image-based arterial input function (AIF) estimation. To investigate the feasibility of quantification of amyloid-beta deposition using the estimated AIF
Morris/Benzinger Amyloid-beta Deposition in Aging: Quantitative Comparison of Two Amyloid Imaging Agents 11/1/2010 S1014 To add beta-amyloid plaque imaging with PET using AV-45 to the longitudinal assessments to KARI.
Eric Lenze, MD Gene Expression Profiling in Stress and Aging 10/1/2009 S0912
Goate, Alison Genomic Search for Susceptibility to Alzheimer's Disease 3/13/2000 S0004
Goate, Alison Does genetic variation in BACE modify risk for Alzheimer's disease? 3/13/2000 S0005
Goate, Alison Cognitive and Linguistic Assessments in the HDD2 Family 4/24/2000 S0008
Meuser, Thomas M. Anticipatory Grief in Caregivers of Individuals with Alzheimer's Disease 11/28/2000 S0011
Hogue, Charles W. Relation between cognitive state before and after CABG surgery 1/11/2000 S0014
Stark, Susan Environmental Barriers in the Homes of Persons with Alzheimer's Disease 1/11/2000 S0015
Braver, Todd S. Cognitive Control in Early Stage Alzheimer's Disease 3/12/2001 S0104
Buckner, Randy L. fMRI Exploration of Memory and Aging and Early-Stage DAT 3/12/2001 S0107
Storandt, Martha Validation of A Simple Cognitive and Fuctional Screen for Mild Cognitive Impairment 5/14/2001 S0107
Lee, Benjamin C.P. Clinical Brain MRI at 3 Tesla 5/7/2001 S0108
Buckner, Randy L. fMRI Exploration of Memory in Aging and Early-stage DAT 5/14/2001 S0110
Villareal, DennisT. DHEA+Exercise: Effect of Sarcopenia & Osteopenia of Aging 6/18/2001 S0111
Galvin, James E. Safety of Galantamine Hydrobromide to Placebo in Patients with Dementia with Lewy Bodies. 6/7/2001 S0112
Buckner, Randy L. Feasibility study for ADRC Project 4 fMRI 6/14/2001 S0113
Balota, Dave A. Differentiating Primary Progressive Aphasia and Dementia of the Alzheimer's Type 6/15/2001 S0114
Jacoby, Larry L. Training Recollective Memory in Early Stage DAT 6/19/2000 S0119
Lee, Benjamin C.P. MR Diffusion Tensor Imaging of Alzheimer's Disease 1/8/2001 S0120
Dyer, Carol Psychosocial Aspects of Predictive Genetic Testing for Early Onset Familial Dementia 1/8/2001 S0122
Dromerick, Alexander W. Can the ISP be Used to Evaluate Mild Vascular Cognitive Impairment 1/1/2001 S0123
Carpenter, Brian Patient-valued Outcomes: Concordance with Families 1/10/2001 S0124
Steffen, Ann The dementia caregiving skills program 10/25/2001 S0128
Morris, John C. Assessment measures for AD primary prevention trials 11/5/2001 S0129
Galvin, James E. Efficacy and safety of LY450108 in patients with probable AD 11/8/2001 S0130
Morris, John C. Evaluation of diagnostic tests for Mild Cognitive Impariment and Alzheimer's disease 11/9/2001 S0131
Morris, John C. ADRC driving deceions supplement 11/16/2001 S0132
Morris, John C. International, Web-based Database Registry of patients with primary progressive aphasia 3/1/2001 S0137
Meuser, Thomas M. Loss Recognition & Contextual Awareness in the Alzheimer's Caregiver-Spouse Relationship 3/4/2002 S0202
Galvin, James E. effects of galantamine and donepezil on sleep and attention and gastrointestinal 1/24/2002 S0203
Morris, John C. Safety and Efficacy of LY450139 in Subjects with Mild to Moderate Alzheimer's Disease 4/29/2002 S0206
Coats, Mary Key Features Pilot Inventory 5/6/2002 S0207
Carpenter, Brian Stability of Patient-Valued Preferences 6/5/2002 S0209
Galvin, James E. controlled trial of simvastatin to slow the progression of Alzheimer's disease 6/19/2002 S0211
d'Avossa, Giovanni Visual Tasks for the Assessment of Parietal Dysfunction in AD 6/18/2002 S0215
Csernansky, John G. Cortciolimbic degeneration and treatment of dementia 7/15/2002 S0217
Carpenter, Brian Family-Level Assessment of Patient-Valued Preferences 8/21/2002 S0218
Perkinson, Margaret A. In-Home Exercise Programs for Persons with Dementia 8/14/2002 S0219
Holtzman, David M. Functional analysis of astrocyte-derived apoE3 and apoeE4 3/31/2002 S0223
Lach, Helen Factors influencing safety in the home care of people with dementia 12/12/2002 S0302
Holtzman, David M. Alzheimer's Disease Biomarkers Research Study 4/18/2003 S0307
Galvin, James E. Lewy body dementias 4/25/2003 S0308
Galvin, James E. safety and efficacy of MK-0677 25 mg in slowing progression of AD 7/18/2003 S0315
Xiong, Chengjie Effects of Alzheimer Diagnosis Disclosure 8/19/2003 S0320
Galvin, James E. Exploring Psychosocial Determinants of Intention to Screen for Memory Loss 8/26/2003 S0321
Buckner, Randy L. Measures of Cognition 9/8/2003 S0325
Buckles, Virginia Handwriting as a predictor of neurodegenerative disease 10/27/2003 S0332
Wilkins, Consuelo Vitamin D Deficiency in African Americans with Dementia 11/11/2003 S0336
Zlokovic, Berislav Activated protein C in Alzheimer's disease 1/23/2004 S0403
Galvin, James E. Cognitive Change in Parkinson's Disease (CCPD) 3/5/2004 S0409
Kirchhoff, Brenda Functional-Anatomic Studies of Memory and Cognition 3/25/2004 S0410
sheline, yvette Treatment Outcome Of Vascular Depression 3/31/2004 S0412
Thomas, Ayanna Metamemory Deficits in Alzheimer's Disease 4/16/2004 S0415
Overkamp, Wendy A Survey of Older Adult Preferences for Interior Design Elements for Homelike Environments 4/29/2004 S0418
McDaniel, Mark Aging and Prospective Memory: A Multiprocess Analysis 6/17/2004 S0423
Buckner, Randy L. Alzheimer's Disease Neuroimaging Initiative 5/1/2004 S0424
Beau Ances MD, PhD Neuroimaging Biomarkers of Rapidly Progressive Dementia: A Prospective and Retrospective Study 6/29/2011 S1104 Determine if MRI images can assist in the early diagnosis of rapidly progressive cognitive decline.
Morris, John C. Study of Single Ascending Doses of AAB-001 in mild to moderate AD 7/23/2004 S0425
Storandt, Martha Word Recall 8/23/2004 S0430
Csernansky, John G. Corticolimbic Degeneration and Treatment of Dementia 8/20/2004 S0431
Mintun, Mark FDG Ė PIB correlations in nondemented vs. DAT 10/29/2004 S0434
Morris, John C. Trial of AAD-001 (ELN116727) in patients with mild to moderate AD 12/2/2004 S0502
Liscic, Rajka Cognitive Profiles of Early Onset FTD and DAT (CDR 0.5): 12/15/2004 S0504
Grant, Betsy Motivation of Normal Adults to participate in AD research 12/16/2004 S0505
Powers, William Cerebral Vascular and Metabolic Mechanisms in Alzheimerís Disease 1/31/2005 S0509
Galvin, James E. Evaluation of the AD8 as a self-rating tool 3/1/2005 S0512
Morris, John C. Alzheimer's Disease Neuroimaging Initiative 3/4/2005 S0513
Galvin, James E. Tolerability and Biomarker Assessment in Subjects with Mild to Moderate AD 6/20/2005 S0516
Bateman, Randall In Vivo metabolism of Amyloid-beta in Alzheimer's disease 6/26/2005 S0518
Nathaniel Lucena Brain and Self-Reported Navigation 6/29/2011 S1105 Does age predict self-reported navigation skill? Does regional brain volume predict self-reported navigation skill? Does brain volume mediate the relationship between age and navigation skill?
Buckner, Randy L. Structure and Cognition (LifeSpanII) 7/20/2005 S0519
Larsen, Randy Emotional Aging and Alzheimer's Disease 8/26/2005 S0523
Csernansky, John G. Stress, Glucocoriciods and Alzheimer Disease 8/29/2005 S0524
Snider, B. Joy LY2062430: Multiple-Dose safety in Subjects with Mild to Moderate AD and Healthy Volunteers 11/14/2005 S0531
Lynch, M.D., John P Medicare Coordinated Care Demonstration Project 11/14/2005 S0532
Duntley, Stephen Tolerability of GHB in Alzheimer's population 11/17/2005 S0533
Gregory Zipfel, MD A Randomized, Investigator- and Subject-Blind, Sponsor-Open, Placebo-Controlled Study to Examine the 12/22/2010 S1016 To look at the effect of a single intravenous (in the vein) dose of an investigational drug (PF-04 To explore how the body reacts to (pharmacokinetics) a single intravenous dose of the study drug ( To see how or if the study drug (PF-04360365) changes how much A is in blood or CSF after a singl To describe the safety and tolerability of a single intravenous dose study drug (PF-04360365) in p
John Morris Changes in extracellular tau is driven by H1 and H2 tau haplotypes 3/8/2011 S1101 To obtain and culture fibroblasts from non-demented controls expressing the H1/H2 tau haplotype To measure extracellular tau in fibroblasts expressing the H1 or H2 tau haplotype
Dmitriy A Yablonskiy, PhD Quantitative Evaluation of Changes in the AD brain Using Advanced MRI 4/26/2011 S1102 To compare GEPCI images obtained in five AD subjects with well-established disease with five normal age-matched subjects. To compare qBOLD data obtained in five AD subjects with well-established disease with five normal age-matched subjects.
Siekyeong Kim Alcohol use and brain functional connectivity 4/30/2012 S1201 To ascertain the effect of alcohol on rs-fcMRI in cognitively normal middle aged and older adults
Timothy Miller, MD, PhD. Determining the half-life of SOD1 in the CSF 8/29/2012 S1202 Determining the half-life of SOD1 in human CSF using stable isotope labeling kinectics Development work in conjunction with Randy Bateman for determining half-life of TAU
B. Joy Snider Tests: The new age of dementia diagnosis 10/10/2012 S1204 Evaluate the impact of CSF biomarkers on clinician diagnosis Evaluate the impact of CSF biomarkers on clinician confidence in diagnosis Evaluate the impact of CSF biomarkers on clinician treatment plan
Randall J Bateman In Vivo metabolism of Amyloid-beta in human CSF; A blood isotope labeled amyloid-beta test for AD 10/12/2012 S1203 To determine if CSF Aő≤ synthesis and/or clearance is altered in subjects with dementia of the Alzhei The next step is to measure Aő≤ kinetics in blood using the SILK technique. Propose to test the hypothesis that blood A Beta isoform kinetics are disturbed in AD. 2011 Specific aim 1 will measure AB isoform production and clearance in blood using existing stable
John C. Morris, Matthew Gabel Disclosure of Individual Research Results in AD: Perceptions of At-Risk Asymptomatic Participants 10/22/2012 S1205 Develop a survey to assess participants’ interest in the disclosure of their individual results. Educate the experimental group and reassess perceptions of and interest in disclosure. Examine responses as a function of potential modifying factors (e.g. age, political ideology). Examine how study subjects compare with a nationally representative sample on the survey.
Randall Bateman DIAN-TU-001 10/24/2012 S1206 test safety and efficacy of two disease-modifying treatments for dominantly inherited AD test effects of treatments on biomarkers (CSF and imaging) in dominantly inherited AD test cognitive measures in presymptomatic individuals in dominantly inherited AD compare two amyloid imaging agents in dominantly inherited AD
Cathy Roe, PhD Driving Performance in Preclinical Alzheimer's Disease 12/13/2012 S1207 Is preclinical AD a risk factor for impaired driving both at baseline and at longitudinal follow-up? Are cognitive reserve factors associated with driving performance at baseline and follow-up? Are navigational impairments risk factors for impaired driving at baseline and folllow-up?
Andrea Denny Ethnic differences in willingness to assent to brain donation 12/21/2012 S1208 What factors among ethnically diverse research participants influence brain donation? What are differences among elders in ethnic groups in the likelihood to assent to brain donation?
Dr. David Kaufman Behavioral and Electrophysiological Correlates of Attentional Control Deficits in Early-Stage AD 4/28/2013 S1301 Very mild AD will lead to a reduction in the maintenance of task context Very mild AD will lead to altered neural activity associated with conflict processing The aforementioned behavioral and electrophysiological correlates will be positively correlated
yvette Sheline Escitalopram Effects on CSF AB Total Concentration 5/1/2013 S1302 Compared to controls, subjects who get the 20mg/dayx2wks will have lower CSF concentration of A-beta
Nupur Ghoshal/ Clay Semenkovich Clinical and Biomarker Characterization of Inherited Frontotemporal Dementia 5/7/2013 S1303 A cohort of FTD caused by mutation in MAPT and GRN will be established, cognitively characterized, a Use plasma and CSF to establish tau biomarker profiles that are unique to presymptomatic individuals
Mitchell Sommers False hearing and cognitive control in DAT 8/12/2013 S1304 Determine if impaired cognitive control in DAT affects response bias Determine if individuals with DAT rely more on context for speech perception
David Van Essen Lifespan Pilot Supplement for WashU-UMinn Human Connectome Project (HCP) Consortium 8/16/2013 S1305 To determine what modifications of current HCP procedures are needed for older adults To compare data acquired by modified HCP methods to data from previous studies in older adults To estimate effect sizes to inform group sizes needed to demonstrate age differences in connectivity To pilot behavioral phenotyping inolder adults using NIH Toolbox and other HCP measures
David Carr Theraputic effects of intransasally-administered insulin in adults with aMCI or mild AD 10/14/2013 S1306 To examine the effects of intranasally-administered insulin (INI) on cognition in aMCI and AD To examine the effects of INI on entorhinal cortex and hippocampal atrophy in aMCI and AD To examine the effects of INI on CSF biomarkers in aMCI and AD Exam global measures of cognitive performance over 12 months of INI treatment compared to placebo
Tammie Benzinger F 18 T807 Tau PET Imaging of Alzheimer’s Disease 10/15/2013 S1307 Perform human in vivo tau imaging using F 18 T807 (aka 18F-AV1451) in 100 participants age 18 and ol Develop quantitative analysis methods for F 18 T807 PET scans. Correlate regional quantitative T807 binding potentials (BPs) with (a) progression of cognitive impa
Beau Ances MD, PhD Chronic Co-Morbid Conditions in HIV+ U.S. Adults on Highly-Active Anti-Retroviral Therapy (HAART) 5/9/2011 S1103 To identify of HIV affects brain resting state functional connections To identify if HIV accelerates brain aging in resting state functional connections To identify if neuroHAART affects brain resting state functional connections
Alexandra Zaleta Perceived consequences of Alzheimer's disease 9/27/2011 S1106 Characterize perceived consequences of AD via interviews of participants with varying AD experience Consolidate interview results into a measure of perceived consequences for use in a separate study
Ling Bei Analysis of Regionally Specfic Cataract Formation in Alzheimer's Disease Patients 10/5/2011 S1107 Quantify regionally specfic cataract formation with the Scheimpflug camera in DAT patients Compare the properties of cataracts in biomaker (+ and -) DAT patients vs. age-matched controls
Stefan Irion Generation of iPSCs from individuals with different APOE alleles to study AD 10/18/2011 S1108 Derive fibroblasts from individuals with different APOE alleles Generate iPSCs from APOE fibroblasts Differentiate iPSCs into neuronal cell types Develop disease releavnt assyas using differentiated cell types
Denise Head Differential Effects of Stress on Brain Structure and Cognition in Healthy Older Adults 10/16/2013 S1308 Determine the differential influence of cumulative stress/HPA axis activity on brain regions Determine the differential influence of cumulative stress/HPA axis activity on cognitive functions
Dmitriy A Yablonskiy, PhD Quantitative Evaluation of Changes in the AD brain Using Advanced MRI 10/17/2013 S1309 see attached file
Jo Ann Antenor-Dorsey Effect of Sleep on Aerobic Glycolysis and Alzheimer's Disease 10/21/2013 S1310 Determine if sleep disruption is associated with changes in aerobic glycolysis in the default mode n Determine if sleep disruption is associated A-beta plaque deposition in the default mode network
Randall Bateman Anti-Amyloid Treatment in Asymtomatic Alzheimer's Disease (A4 Study) 12/26/2013 S1311 Test the hypothesis that solanezumab, administered as an IV infusion at a dose of 400mg every 4 weeks for 3 years, will slow cognitive decine as compared with placebo in subjects with preclincial AD To test the hypothesis taht solanezumab will slow the decline of preceived function and performance of everyday activities, as compared to placebo
Duntley, Stephen GHB Tolerability Study in AD population 11/22/2005 S0533A
sheline, yvette PET Amyloid Plaque Imaging in Late Life Depression 2/24/2006 S0607
Mintun, Mark amyloid binding properties, pharmacokinetics and safety, of F-AV-19 8/16/2006 S0618
Head, Denise Structural and Psychometric Correlates of Lifetime Engagement in Physical Activity 8/28/2006 S0620
Galvin, James E. Effects of Docosahexaenoic Acid (DHA) in slowing the Progression of AD 10/19/2006 S0622
Palmer, Janice Nurse and Physician Correlation and Percent Agreement 12/26/2006 S0705
Mintun, Mark F-AV-138 in healthy elderly volunteers and patients with AD 3/5/2007 S0712
Morris, John C. Autopsy Program Satisfaction in the Memory and Aging Project 5/1/2007 S0717
Galvin, James E. ACC-001 with QS-21 Adjuvant In Subjects With Mild To Moderate AD 6/15/2007 S0718
Galvin, James E. _PIB Imaging In Lewy Body Disease 7/2/2007 S0719
Zacks, Jeffrey M. Encoding and Remembering Events Across the Lifespan 7/12/2007 S0720
Williams, Monique Insulin Resistance and Depression in Normal Cognitive Aging 8/21/2007 S0724
Galvin, James E. Psychosocial factor promoting aging in place 8/15/2007 S0725
Galvin, James E. PF-04494700 (TTP488) in Participants with Mild-to-Moderate AD 1/11/2008 S0807
Galvin, James E. Effect of Gamma Secretase Inhibition on the Progression of AD 2/6/2008 S0810
Bateman, Randall Resting Brain Metabolism in the Familial Adult Child Study 1/29/2008 S0811
Mintun, Mark Amyloid Imaging in the Adult Children Study 2/20/2008 S0813
Palmer, Janice Experience of Spousal caregivers at nursing home placement 2/22/2008 S0814
Cortese, Michael J. Basis and effect of semantic memory loss in semantic dementia 11/8/1999 S9904
Dyer, Carol Implications for Genetic Testing in Members of Families with Early-onset Familial Dementia 11/8/1999 S9905
Powers, William AIT-082 in Mild Alzheimer's Disease Patients 9/13/1999 S9906
Csernansky, John G. Cortical Degeneration and Treatment Response in DAT 6/7/1999 S9910
Corbetta, Maurizio Functional Imaging Studies of Aphasia Recovery 7/12/1999 S9911
Canfield, Rita H. Psychological and physical stressors of caregiving: Implications for physical health 9/13/1999 S9913
Morris, John C. A multicenter trial of rofecoxib and naproxen in Alzheimer's disease 10/9/1999 S9914
Vijay Sharma Imaging Functional Pgp Transport at the Blood Brain Barrier in Alzheimerís Disease 12/15/2010 S1015 Compare the brain uptake of the Pgp substrate [Tc-99m]sestamibi in AD patients and healthy subjects Compare the brain uptake of [Tc-99m]sestamibi with previously performed [C-11]PIB studies
John Morris and Matthew Gabel Disclosure of Individual Research Results in Alzheimer’s Disease: Perceptions of At-Risk Asymptomatic Participants 6/27/2014 S1401 Educate an experimental group and assess perceptions of and interest in disclosure. Examine responses as a function of potential modifying factors (e.g. age, political ideology). Examine how study subjects compare with a nationally representative sample on the survey.
David Balota Cognitive Training in Prospective Memory 9/10/2014 S1402 whether explicit instruction leads to transfer of learning for prospective memory what type of prospective memory training participants that is most effective for transfer whether the same training works for a CDR .05 sample
Julie Bugg Prospective Memory Commission Errors and Controlled Monitoring Processes in Healthy Aging and Early-Stage Alzheimer?s Disease 10/6/2014 S1403 We aim to examine if two prospective memory outcomes (1) commission errors and (2) controlled monitoring ability distinguish older adults with very mild dementia from healthy older adults We aim to examine the relationship between these prospective memory outcomes and regional brain volumes We aim to examine the relationship between these prospective memory outcomes and hypertension
Alison Goate/Carlos Cruchaga Human cell models of dementia 10/7/2014 S1404 To obtain and culture dermal fibroblasts from individuals carrying causative mutations associated with dementias (MAPT, GRN, C9ORF72, Non-DIAN PSEN1) To obtain and culture dermal fibroblasts from individuals carrying risk variants associated with dementias (PLD3, TREM2, UNC5C) To generate induced pluripotent stem cells (iPSCs) from dermal fibroblasts carrying causative mutations or risk variants associated with dementias
Dave Balota Age Differences in Category Learning Strategies 10/7/2014 S1405 To determine whether individual differences in category learning strategies differ between younger and older adults. To examine the relationship between the volume of brain regions and category learning strategies in healthy older adults.
Randall Bateman, Chihiro Sato Analysis of Tau Kinetics using Infusion of Stable Isotopes 10/29/2014 S1406 What is the Half Life of Tau in the Human Central Nervous System Is CSF Tau increased due to over-production or under-clearance Are Tau Kinetics altered in Alzheimer's Disease How much should Tau be modulated by drugs which Target Tau
Natalie Selsor Disclosure of Individual Research Results in Alzheimer’s Disease: Perceptions of At-Risk Asymptomatic Participants 10/8/2012 Declared Develop a survey to assess research participants’ perceptions of and interest in the disclosure of their own individual research results. Develop information to educate participants on the risks and benefits of disclosure and present this information to the experimental group. Reassess the experimental group’s perceptions of and interest in disclosure following the educational intervention, and reassess the control group after providing (placebo) information unrelated to the study hypotheses. Examine the participants’ responses as a function of potential modifying factors (e.g. age, family history of AD, political ideology).
Holly D. Soares Development of IVD CSF AB42 and Tau Assays 10/12/2012 Declared To define normative ranges in cognitively normal individuals who have remained cognitively normal for a period of 1-3 or 4-5 year follow-up. To define assay specific cutpoints for cognitively impaired individuals at risk of progression to AD dementia between a two to five year period.
Steven Schreiber Histone deacetylase activity in Alzheimer’s disease 10/30/2012 Declared To evaluate acetyl-alpha-tubulin and MAP2c abundance, HDAC6 and Sirt1 activities in CSF from AD patients, age-matched controls and patients with other neurological diseases. To determine whether there is a correlation between CSF HDAC activity and/or abundance of acetyl-alpha-tubulin and MAP2c, and clinical features including degree of cognitive impairment and imaging abnormalities.
Kenneth Kosik Gene expression analysis of MAPT A152T mutation carriers 12/4/2012 Declared Transcriptome sequencing of RNA obtained from patients’ samples. Comparison of differentially express genes compared to human healthy tissue.
Andrea Denny Ethnic differences in willingness to assent to brain donation 12/21/2012 Declared Study aims to determine: What are the factors among ethnically diverse research participants that influence whether or not an individual research participant will assent to brain autopsy? Study aims to determine: What are the differences among elders in different ethnic groups in their likelihood to assent to brain autopsy?
Jonathan Jackson Investigating COMT and Intraindividual Variability 2/1/2013 Declared Determine whether there is a relationship between COMT status and working memory performance in healthy aging and early-stage AD, and whether this relationship is mediated by intraindividual variability in reaction time.
First Name Last Name Reserve variables and the relationship between AD biomarkers and non-cognitive outcomes 2/5/2013 Declared To examine how cognitive and brain reserve variables mediate associations between AD biomarkers (i.e., CSF biomarkers and PIB PET imaging) and non-cognitive outcomes associated with incident AD.
Ingber Adam Reserve variables and the relationship between AD biomarkers and non-cognitive outcomes 2/5/2013 Declared To examine how cognitive and brain reserve variables mediate associations between AD biomarkers (i.e., CSF biomarkers and PIB PET imaging) and non-cognitive outcomes associated with incident AD.
Adam Ingber Reserve variables and the relationship between AD biomarkers and non-cognitive outcomes 2/5/2013 Declared To examine how cognitive and brain reserve variables mediate associations between AD biomarkers (i.e., CSF biomarkers and PIB PET imaging) and non-cognitive outcomes associated with incident AD.
Cruchaga Carlos/Benitez Bruno Identification of rare variants implicated on Alzheimer’s Disease 2/5/2013 Declared To describe the neuropathological findings for the PSEN1, p.E318G carriers
David K Johnson A predictive prognostic model for Alzheimer‚Äôs disease 2/11/2013 Declared Evaluate the reproducibility of a previously constructed Bayseian Belief Network (BBN) in an autopsy-confirmed sample of pure and mixed AD pathology (KADRC; 4 to 8 repeated measures). Extend a previously constructed BBN to include KADRC biomarker data containing ‚Č•3 repeated measures for MRI, amyloid imaging, and CSF. Evaluate convergent validity of the BBN by comparing the model diagnoses to expert diagnoses in very large sample of DAT
Marc Diamond Identification of novel anti-tau antibodies capable of blocking tau propagation 2/13/2013 Declared To test whether novel anti-tau antibodies can block tau seeding induced by human brain lysate
Kummer Axon injury in intracerebral hemorrhage 3/4/2013 Declared Determine the extent of local and global acute axonal injury after ICH using diffusion tensor imaging, and correlate abnormalities with initial neurological status Examine the sub-acute evolution of local and global axonal injury following ICH Examine the chronic evolution of local and global axonal injury after ICH, and determine which is best correlated with long-term outcome Compare radiological biomarkers of axonal injury resulting from ICH with biochemical biomarkers obtained via cerebral microdialysis
First Name Last Name Expert system for diagnosis of Alzheimer's disease 3/5/2013 Declared perform the MMS test of alzheimer's patient to have probalble diagnosis Analyze EEG data of the patient diagnose whether person is suffering from alzheimer's or not
Irfan Tamboli Lipoprotein metabolism in human CSF depending on AD pathology and apoE genotype 6/24/2013 Declared Analysis of apoE fragments and dimers in CSF samples obtained from AD patients and age matched control subjects. Investigate influence of genotype on apoE fragments and apoE dimers in control and AD subjects in CSF samples To address the effect of age on apoE metabolism in human CSF To study metabolism of other apolipoproteins such as apoJ, apoA-II in human CSF depending on AD pathology and apoE genotype
Stephanie Vos The prevalence of amyloid pathology in healthy individuals and patients with mild cognitive impairment: a meta-analysis 8/21/2013 Declared To characterize amyloid prevalence according to baseline cognitive scores (CDR, MMSE, delayed recall) To characterize amyloid prevalence according to age, apoE genotype To characterize amyloid prevalence according to future cognitive scores (CDR, MMSE, delayed recall)
Hyung Jin Ahn Identification of a Plasmin-Resistant Fibrin Fragment ‚Äď a Potential Biomarker for Alzheimer‚Äôs Disease 10/3/2013 Declared Determine if plasmin-resistant fibrin fragment exists in AD patient CSF
Jo Ann Antenor-Dorsey Effect of Sleep on Aerobic Glycolysis and Alzheimer's Disease 10/21/2013 Declared Determine if sleep disruption is associated with changes in aerobic glycolysis in the default mode netowrk in healthy adults Determine if sleep disruption is associated A-beta plaque deposition in the default mode network
Dianne Langford Implications of PINCH in CSF 11/6/2013 Declared Determine if PINCH levels in CSF correspond to neurocognitive status Determine if PINCH levels correspond to markers of immune system decline
Alexandra Zaleta Perceived consequences of Alzheimer's disease 9/24/2011 Declared Generate a systematic and detailed characterization of the perceived consequences of AD in a sample of adults with a variety of AD experience. Consolidate information generated by study interviews into a measure of perceived consequences, to be used later in a separate study of older adults' attitudes about obtaining more information about AD and being screened for AD.
Danny JJ Wang Complexity and synchronicity of resting state fMRI time series in Alzheimer's disease 11/2/2011 Declared To determine if the complexity of BOLD signal time-series decreases in AD, compared to age-matched normal controls To determine if synchonicity, as defined by cross-approximate entropy, can be used to detect differences in functional connectivity between AD patients and normal age-matched controls
BRIAN BENNETT In situ EPR Characterization of Paramagnetic Biomarkers for AD 11/18/2011 Declared Development of Non-Adiabatic Rapid Scanning Electron Paramagnetic Resonance (NARS-EPR) spinomics for the study of biological material Characterization of paramagnetic biomarkers for Alzheimer's disease by NARS-EPR spinomics Structural analysis of AD-related paramagnetic species by computer simulation of EPR data and density functional theory structure calculations
Robert Siman A panel of neurodegeneration biomarkers for Alzheimer's progression 12/7/2011 Declared Evaluate CSF levels of 7 neurodegeneration biomarkers in relation to neurocognitive status Compare CSF neurodegeneration biomarker levels with biomarker evidence for AD neuropathology
Ina Wanner Astrocyte neurotrauma biomarkers in TBI and healthy CSF 1/6/2012 Declared Determine proteomic differences between healthy subject CSF and brain trauma patients CSF Analyze difference of new astrocytic trauma markers in TBI patients' versus healthy subjects' CSF by Westernblotting Mass spectrometric quantification of neurotrauma biomarker candidates in healthy subjects and TBI patients CSF Evaluate blood brain barrier compromise by quantifying plasma and CSF markers in healthy and TBI patients CSF
Joseph Dougherty Screening for antigens present in hypothalamic neurons 2/21/2012 Declared Identify new antigens present in hypothalamic neurons
Stephen M. Strittmatter Measuring Levels of Amyloid Beta Oligomers Capable fo PrP Interaction 4/22/2012 Declared Use Novel Assay to Measure PrP-Interacting Aß Oligomers in AD versus Control Samples
Anja Schneider miRNA patterns in human CSF as an antecedent biomarker in AD 6/15/2012 Declared identification of miRNA signatures in CSF to identify preclinical stages of AD
Charles DeCarli NACC MRI Genotype Association Studies 7/5/2012 Declared Acquire MRI data related to TCV and Hippocampal estimates from NACC participating sites Match MRI data with ADGC acquired genotype data on NACC enrolled subjects Perform candidate gene studies based on novel findings related to genetic regulation of intracranial and hippocampal volumes If sufficient site participation, perform endophenotype GWAS using these MRI measures
Alison Goate/Oscar Harari Identification of genetic variants associated with novel AD CSF biomarkers 7/24/2012 Declared To identify CSF analytes associated with traditional AD biomarkers To identify genetic variants associated with candidate CSF analytes
Ghoshal, Nupur Clinicopathological correlations of MAPT A152T mutation carriers 7/24/2012 Declared To characterize individuals carrying the MAPTA152T variant in terms of clinical, pathological, and molecular phenotypes to determine where they fit into the spectrum of disorders ranging from Alzheimer’s disease (AD) to frontotemporal dementia (FTD) associated with A152T.
Yueming Li Characterization of ÔĀß-secretase in Alzheimer‚Äôs disease brains 12/17/2013 Declared Examine the activity and specificity of g-secretase in AD and control brains
Li, Ien Patch-Based Analysis of Anatomical Brain Asymmetry 1/3/2014 Declared Compare structural asymmetry patterns in diseased individuals versus healthy controls Assess cognitive measures with brain asymmetry from structural MRI scans
Jennifer Molano The Effect of Alzheimer‚Äôs Disease Biomarkers and Sleep on Cognitive Performance 1/24/2014 Declared CSF levels of Aő≤42, tau, ptau181, tau/Aő≤42, and ptau181/Aő≤42 indicating AD pathology will be associated with worse psychometric performance on tests of memory and/or executive functioning among cognitively normal adults, both cross-sectionally and longitudinally. Sleep efficiency will be an effect modifier on psychometric scores, with worse sleep efficiency correlating with worse psychometric performance on tests of memory and/or executive functioning cross-sectionally and longitudinally, after accounting for any effect of CSF AD biomarkers.
Eric J Kremer Screen for a biomarker in early satges of late onset AD 2/21/2014 Declared Screen CSF from AD patients for the presence of a cleaved presynaptic protein diminished in early satges of late onset AD
Anish Mitra The Gene expression basis of amyloid distribution in Alzheimer's Disease 3/1/2014 Declared Relate spatial patterns of gene expression to the spatial topography of amyloid distribution in the brain Investigate genes whose spatial expression profile matches amyloid and aerobic glycolysis in the brain
Sebastian Palmqvist Comparison of large cohorts examining AD biomarkers 3/10/2014 Declared Verify the number of patients that have undergone CSF, PET, MRI, and examine the follow-up time and inclusion/exclusion procedures Compare this to other large cohorts such as AiBL, ADNI, Descripa among others.
Laura Piccio TREM2 as a key player and a potential biomarker in Alzheimer’s disease. 4/28/2014 Declared To determine whether the CSF and serum levels of sTREM2 are associated with clinical AD and/or with a TREM2-variant carrier status.
DENISE MAUE DREYFUS An item-level analysis of frequently missed items on the Mini Mental State Exam in cognitively normal older adults. 7/7/2014 Declared Determine which items on MMSE are most frequently missed by CDR0 adults Determine if these items relate to demographic characteristics and family history perform a survival analysis to determine if certain items are associated with future progression to AD
Kevin Yarasheski ER stress, bile salts, and amyloid kinetics 7/14/2014 Declared To determine the effects of tauroursodeoxycholic acid administration on amyloid production and clearance rates in adults with mild cognitive impairment To determine the effects of tauroursodeoxycholic acid administration on PiB accumulation in adults with mild cognitive impairment
William Fairbrother Analysis of Defective pre-mRNA Splicing of Disease-causing PSEN1 Genetic Variants in Biological Samples from Alzheimer's Disease Patients 8/11/2014 Declared Validate results obtained using a high-throughput splicing assay with respect to causal PSEN1 mutations in biological samples, such as postmortem brain samples and/or blood, from Alzheimer's disease patients.
Masaaki Matsuoka Calmodulin-like skin protein and its regulators in Alzheimer's disease 8/11/2014 Declared Involvement of CLSP in the Alzheimer's pathogenesis Diagnostic value of CLSP in Alzheimer's disease
test test Ŗ? hffcffg 9/4/2014 Declared test Ŗ?
Sharda Umanath Cognitive Training in Prospective Memory 9/10/2014 Declared whether explicit instruction leads to transfer of learning for prospective memory the type of prospective memory training participants that is most effective for transfer whether the same training works for a CDR .05 sample
Gregory Day Predictors of speed of progression in dementia 9/11/2014 Declared To characterize the clinical and paraclinical features of participants with suspected or confirmed rapidly progressive dementia. To identify clinical and paraclinical measures that accurately identify participants with rapidly progressive dementia. To identify clinical and paraclinical measures that accurately predict final diagnoses in patients with rapidly progressive dementia. To identffy clinical and paraclinical measures that assocaite with rapidly progressive, typically progressive and slowly progrssive dementia.
Chris Wahlheim Age Differences in Category Learning Strategies 10/7/2014 Declared To determine whether individual differences in category learning strategies differ between younger and older adults. To examine the relationship between the volume of brain regions and category learning strategies in healthy older adults.
Francis Hane Testing affinity tags on AD brain samples 10/24/2014 Declared We will test the affinity of a variety of novel affinity tags on pathological AD brain tissue.
John C Morris Accelerators and Protectors of Transitioning to Symptomatic AD 10/26/2014 Declared Examine Adult Children Study participants who have been rated CDR>0 Examine their clinical, cognitive, imaging, biofluid, and genetic features compared with ACS participants who remain CDR0
Erin Norris Pathological consequences of hypertension in Alzheimer's disease 10/28/2014 Declared Identify molecular changes at the neurovascular unit in hypertensive humans with AD
Randall Bateman Analysis of Tau Kinetics using Infusion of Stable Isotopes 10/29/2014 Declared What is the Half Life of Tau in the Human Central Nervous System Is CSF Tau increased due to over-production or under-clearance Are Tau Kinetics altered in Alzheimer's Disease How much should Tau be modulated by drugs which Target Tau
Teodoro Bottiglieri Plasma and Cerebrospinal fluid biomarkers of the methylation cycle in cognitively normal and mild dementia of the Alzheimer type. 11/6/2014 Declared To determine and compare metabolites related to methionine metabolism and methylation in plasma and CSF from a cohort of subjects who cognitively normal and with mild dementia of the Alzheimerís type. To determine the relationship between metabolites related to methionine metabolism and methylation with other biomarkers of Alzheimerís disease (i.e.ApoE genotype, beta-amyloid 1-40 and 1-42, Tau and p-Tau) in plasma and CSF. To determine if metabolites of the methionine cycle and methylation are correlated with and predictive of changes in dementia clinical scores and brain imaging data in subjects enrolled in the ďLongitudinal studies of healthy aging and dementiaĒ.
Investigator Project Title Requested ID Aim 1 Aim 2 Aim 3 Aim 4